Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • Log out
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Microbiology Reviews
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Review

Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World?

Alejandro Beceiro, María Tomás, Germán Bou
Alejandro Beceiro
Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, A Coruña, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Tomás
Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, A Coruña, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Germán Bou
Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, A Coruña, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: German.Bou.Arevalo@sergas.es
DOI: 10.1128/CMR.00059-12
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

SUMMARY

Hosts and bacteria have coevolved over millions of years, during which pathogenic bacteria have modified their virulence mechanisms to adapt to host defense systems. Although the spread of pathogens has been hindered by the discovery and widespread use of antimicrobial agents, antimicrobial resistance has increased globally. The emergence of resistant bacteria has accelerated in recent years, mainly as a result of increased selective pressure. However, although antimicrobial resistance and bacterial virulence have developed on different timescales, they share some common characteristics. This review considers how bacterial virulence and fitness are affected by antibiotic resistance and also how the relationship between virulence and resistance is affected by different genetic mechanisms (e.g., coselection and compensatory mutations) and by the most prevalent global responses. The interplay between these factors and the associated biological costs depend on four main factors: the bacterial species involved, virulence and resistance mechanisms, the ecological niche, and the host. The development of new strategies involving new antimicrobials or nonantimicrobial compounds and of novel diagnostic methods that focus on high-risk clones and rapid tests to detect virulence markers may help to resolve the increasing problem of the association between virulence and resistance, which is becoming more beneficial for pathogenic bacteria.

INTRODUCTION

Bacteria are present both inside and on the surface of the human body, especially on the skin and the mucous membranes. Most of these bacteria are innocuous, many are beneficial, and some are even necessary. However, other bacteria, which are categorized as pathogens, are able to colonize, invade, and damage the host and thus cause illness. Pathogenicity is an ability of an agent to cause disease, and the pathogenic bacteria possess several factors that enable them to enhance their virulence (i.e., the degree of pathogenicity). Most pathogens make use of a combination of two properties to cause disease: (i) toxicity, the degree to which a substance causes harm, and (ii) invasiveness, the ability to penetrate into the host and spread (1). The final balance of an infectious disease process will depend on the virulence or pathogenicity of the microbe as well as the host status in relation to risk factors such as immune status, age, diet, and stress, which determine the host susceptibility to infection. Hosts and bacteria have coevolved over millions of years, during which pathogenic bacteria have modified their virulence to adapt to the host defense systems. This contrasts with the relatively recent evolution of antimicrobial resistance (defined as the ability of an organism to resist the action of an antimicrobial agent to which it was previously susceptible). Although medical practice has limited the development and spread of pathogens, this has led to a global increase in antibiotic resistance. The evolution and spread of resistance are relatively recent and have occurred mainly in the last 50 years, i.e., since antibiotics were first used. Therefore, virulence and resistance have evolved over very different timescales.

Despite the difference in the evolution of these processes, they share some common characteristics. (i) From a biological point of view, both processes are necessary for bacteria to survive under adverse conditions. Virulence mechanisms are necessary to overcome host defense systems, and the development of antimicrobial resistance is essential to enable pathogenic bacteria to overcome antimicrobial therapies and to adapt to and survive in competitive and demanding environments (new niches). Immune defense systems and antibiotic pressure represent bottlenecks for survival of the bacterial population, as they greatly limit the capacity for growth and lead to decreased microbial diversity (2, 3). (ii) Virulence and resistance factors are similar in that most of the determinants have been transmitted between species or genera by horizontal gene transfer (HGT); the transfer of DNA fragments (mobile genetic elements [MGEs]) is probably the main genetic mechanism of dissemination and coselection of virulence and resistance genes, although other mechanisms such as compensatory or adaptive mutations may also be involved (4, 5), as will be discussed below. (iii) Antibiotic resistance is often associated with infection and is therefore also related to virulence, as in the cases of biofilm-producing microorganisms or intracellular infections (6, 7). (iv) Other characteristics that are common to virulence and resistance include the direct involvement of efflux pumps (8), porins (9), cell wall alterations (10), and two-component systems that activate or repress the expression of various genes, such as those involved in resistance and virulence (11).

In healthy individuals, opportunistic pathogens are not able to produce infection because they lack the necessary mechanisms of toxicity and invasiveness that enable primary pathogens to overcome the host immune system. However, in some individuals, such as immunocompromised patients, opportunistic pathogens can produce infection, which can be prevented mainly by the use of antimicrobial therapies. Certain multiresistant opportunistic species, such as Pseudomonas aeruginosa and Acinetobacter baumannii, can colonize niches where many other species cannot survive (environments with high antibiotic pressure) and can even displace the commensal flora. This is one example of how antimicrobial resistance can increase the virulence or fitness of certain species in some environments, often helping these species to colonize new niches. Therefore, although antibiotic resistance is not in itself a virulence factor, in certain situations it is a key factor in development of infection, and it may be considered a virulence-like factor in specific ecological niches which antibiotic-resistant bacteria are able to colonize. This is especially true in the hospital environment (intensive care units, burn units, etc.), in which if a opportunistic pathogen is drug resistant, it can cause disease more readily (12). In environments where selective antibiotic pressure prevails, some opportunistic pathogens are able to colonize new ecological niches because of their plasticity and ability to adapt through the acquisition or development of mechanisms of resistance and persistence.

The use of antibiotics has changed the natural evolution of bacteria by reducing susceptible pathogenic populations and increasing resistant populations. Resistance is often associated with a fitness cost because the genetic burden required for resistance may be deleterious in antibiotic-free environments. In this case, restriction of the use of antibiotics has been proposed, with the aim of eradicating resistant bacteria (13). However, the genetic background of resistant pathogens allows them to persist in the presence of minimal concentrations of antibiotics or even in the absence of these, as discussed throughout this review (14). Hypermutation, compensatory mutations, and cross coselection are a few of the many mechanisms that favor the persistence of resistant pathogens and even, in some cases, selection of the most virulent and most resistant pathogens.

This review considers the relationship between virulence and resistance, including the role of increasing resistance in relation to fitness costs. Increased resistance is associated in most cases, either directly or indirectly, with decreased virulence and fitness. However, evidence also shows the opposite, and it is increasingly evident that the relationship is often of greater benefit to the pathogen, resulting in a growing public health problem.

This review also considers the impacts of resistance to the main antimicrobial agents used in clinical practice as well as the genetic events associated with evolution of pathogens on virulence and/or fitness costs. In vivo and in vitro laboratory examples and clinical studies of specific pathogens are presented, and the interplay between both of these important bacterial characteristics is analyzed in detail. Because of the importance of the interactions between resistance and virulence, these aspects are always considered together. Partial analyses that consider aspects of resistance and/or virulence separately were disregarded for the purposes of this review.

RELATIONSHIP BETWEEN MECHANISMS OF ANTIMICROBIAL RESISTANCE AND VIRULENCE

Throughout this section we will refer frequently to Table 1, in which we have attempted to clarify and summarize the examples given in the text of relationships between virulence and resistance determinants in the most commonly studied or clinically relevant pathogens. To simplify the numerous studies reported in the literature, we have classified the examples according to families of antibiotics for which the resistance mechanisms have been examined.

View this table:
  • View inline
  • View popup
Table 1

Mechanisms of antimicrobial resistance and virulence

Resistance to β-Lactams and Impact on Virulenceβ-Lactam antibiotics are a large class of antibiotics that have a β-lactam ring in their molecular structure. They are the most widely used antibiotics and include penicillin derivatives, cephalosporins, monobactams, carbapenems, and β-lactamase inhibitors.

Resistance to β-lactams involves several mechanisms, which are different in Gram-positive and Gram-negative bacteria. In Gram-positive microbes, mutations and/or reduction of or expression alterations in penicillin-binding proteins (PBPs) are the most important mechanisms, followed by β-lactamase production. Conversely, in Gram-negative microorganisms, the most prevalent mechanism of β-lactam resistance is the production of β-lactamases, followed by permeability alterations, extrusion by efflux pumps, and to a lesser extent PBP alterations. Before further discussion of this topic, it is important to point out that interpretation of the data and any conclusions drawn may differ greatly depending on the specific microorganism under study, even within a family, e.g., Enterobacteriaceae. Therefore, caution must be exercised when discussing this topic, and conclusions should be assumed to be organism specific.

PBP modifications.The PBPs involved in resistance and virulence are PBP2 (encoded by mecA) (in Staphylococcus aureus), PBP2b-PBPX (in Streptococcus pneumoniae), and PBP7-8 (in A. baumannii) (Table 1).

Previously reported data suggest that expression of homogeneous methicillin resistance in S. aureus influences the biofilm phenotype and attenuates virulence (it reduced protease production and significantly reduced virulence in a mouse model of device-related infection) (15). Clinical isolates of S. aureus can express biofilm phenotypes promoted by the major cell wall autolysin and the fibronectin (Fn)-binding proteins or the polysaccharide intercellular adhesin (PIA) and the polymeric N-acetylglucosamine (PNAG), which are synthesized and exported by proteins encoded by the icaADBC gene cluster. Biofilm production in methicillin-susceptible S. aureus (MSSA) strains is associated with PIA/PNAG, whereas methicillin-resistant isolates express an Atl/FnBP-mediated biofilm phenotype (which produces a proteinaceous biofilm), which suggests a relationship between biofilm production and susceptibility to β-lactam antibiotics (16). Rudkin et al. reached similar conclusions after demonstrating that methicillin resistance reduces the virulence of health care-associated methicillin-resistant S. aureus (MRSA) by interfering with the agr quorum-sensing (QS) system in such a way that the ability of the bacteria to secrete cytolytic toxins is reduced (15). These authors state that methicillin resistance induces cell wall alterations that affect the Agr quorum-sensing system of the bacteria. This leads to reduced expression of the toxin and lowered virulence in a murine model of sepsis. This interesting finding may explain why some strains of hospital-acquired MRSA show a reduced ability to spread in the community. It may also explain the recent increase in the incidence of community-associated MRSA (CA-MRSA) strains, which typically express less penicillin-binding protein 2a (encoded by mecA) and thus maintain full virulence for success in the community setting. This is a typical example of how the acquisition of resistance to a specific antibiotic (oxacillin) is related to a decrease in virulence.

However, Queck et al. described the presence of a psm gene (psm-mec), associated with staphylococcal methicillin resistance, which encodes a mobile genetic element (MGE), SCCmec (17). Phenol-soluble modulins (PSMs), which are staphylococcal cytolytic toxins, play a crucial role in immune evasion. Although all known PSMs are core genome encoded, Queck et al. described this gene inside the SCCmec clusters of types II and III in a series of staphylococcal strains, including strains of S. aureus, S. epidermidis, S. saprophyticus, S. pseudointermedius, and S. sciuri. This very interesting study revealed a previously unknown role for methicillin resistance clusters in staphylococcal pathogenesis and showed that both antibiotic resistance and virulence determinants may be combined in staphylococcal MGEs (the exception to the above-mentioned rule).

S. pneumoniae was previously considered to be universally susceptible to penicillin. However, reports of isolates with decreased susceptibility to penicillin have increased worldwide in recent years (18). In one study, Rieux et al. analyzed the relationship between acquisition of β-lactam resistance and loss of virulence in S. pneumoniae (19). The authors transformed a virulent and penicillin-susceptible strain with pbpX and pbp2b from a penicillin-resistant strain to assess the relationship between acquired resistance and virulence. After transformation, the virulence of these receptor strains was significantly reduced.

Penicillin resistance in S. pneumoniae caused by PBP modifications may occur via different mechanisms, such as acquisition of an additional low-affinity PBP, overexpression of an endogenous low-affinity PBP, alteration of endogenous PBPs by point mutations or homologous recombination, or a combination of these (20). Several studies have assessed whether resistance to this first-line antibiotic may affect the virulence of pneumococci. For instance, Azoulay-Dupuis et al. examined the relationship between virulence and penicillin susceptibility in an experimental murine model of peritoneal infection and capsular type, using 122 clinical strains of S. pneumoniae belonging to 24 different serotypes (21). All 32 virulent strains were penicillin susceptible, while all 41 strains with reduced susceptibility to penicillin were avirulent, independently of the serotype. In a later study, Fernandez et al. used a rabbit model of meningitis to test the inflammatory activity induced by three different strains of pneumococci, belonging to serotypes 3, 6B, and 23F (the prevalent serotypes in Western Europe), with different susceptibilities to β-lactams (22). The authors' conclusions supported the idea that penicillin-resistant pneumococcus isolates are avirulent in immunocompetent mice, regardless of the isolation site (23, 24). Overall, the data suggest that acquisition of penicillin resistance in pneumococci is associated with loss of virulence in different models of infection.

Data from studies of Gram-negative bacilli are very scarce, and the impact of PBP alterations on virulence is unclear. With the aim of simplifying the interpretation of the data, this review will focus only on A. baumannii. Russo et al. have demonstrated that PBP7-8 contributes to both the in vitro and in vivo survival of A. baumannii (25). These authors screened a random transposon mutant library and identified a mutant, AB307.27, which contained a transposon insertion in pbpG, encoding the putative low-molecular mass PBP7-8. This mutant showed lower survival in a rat soft tissue infection model and in a rat pneumonia model than the isogenic wild-type strain. Although no clear data have been obtained with regard to the putative role of PBP alterations in β-lactam resistance of A. baumannii (they are an important resistance mechanism in other species, such as P. aeruginosa), it has been suggested that such alterations (at least in PBP7-8) may lead to a decrease in the virulence of A. baumannii (25, 26).

β-Lactamase expression.As stated above, β-lactamase production is the main mechanism of β-lactam resistance in Gram-negative pathogens. However, it is not clear whether expression of β-lactamases affects the virulence or fitness of these bacteria or whether any general conclusions can be drawn. Examples of β-lactamases previously reported to be involved in virulence are listed in Table 1.

Escherichia coli ST131 (O25:H4), which produces the CTX-M-15 extended-spectrum β-lactamase (ESBL), has emerged internationally as a multidrug-resistant (MDR) pathogen (see Highly Virulent Multiresistant Worldwide Disseminated Clones, below). This β-lactamase and other CTX-M-type enzymes are also prevalent in other virulent E. coli clones, such as Shiga toxin-producing serotype O111:H8 (27) and O26:H11 (28), and even in E. coli strains isolated from chicken and pig farms in Spain, highlighting the potential risk of zoonotic transmission (29). Thus, virulence factors have been identified in E. coli isolates that produce CTX-M-type ESBL (30), and E. coli ST131, which produces the widespread NDM-1 enzyme, has been found to exhibit a wide array of virulence factors (31). Therefore, β-lactamase enzymes and virulence genes may coexist in specific E. coli clones worldwide, possibly as a result of stepwise coevolution processes.

However, it is not clear whether the presence of a specific β-lactamase gene impairs the ability of the microorganism to cause damage, in terms of host colonization, invasiveness (pathogenicity) or fitness costs, and robust conclusions cannot be drawn from the data obtained so far. At least in E. coli, the production of a CTX-M-1 enzyme does not appear to affect virulence. Dubois et al. reported the isolation, from a patient with neonatal meningitis, of an E. coli strain with three different plasmids, one of which produced CTX-M-1 β-lactamase (32). The plasmid that encoded the β-lactamase did not increase the incidence of meningitis in a newborn mouse model, thus suggesting that the CTX-M-type enzyme does not increase the virulence of E. coli in this animal model (32). Very similar findings were obtained in a study that evaluated the virulence of P. aeruginosa carrying bla IMP (a metallo-β-lactamase gene) in an endogenous bacteremia model, and it was concluded that the presence of this enzyme did not significantly affect the virulence of the P. aeruginosa PAO1 parent strain (33).

The impact of β-lactamases in relation to biological fitness costs in bacteria has been poorly studied. The interaction between resistance mechanisms and bacterial fitness will decide the fate of a specific bacterial strain once the selective pressure exerted by antibiotics disappears. In a study of this topic, our group demonstrated quantitative changes in the peptidoglycan composition in E. coli strains expressing OXA-24, OXA-10-like, and SFO-1 (with its upstream regulator AmpR) β-lactamases; the changes were reflected by a decrease in the level of cross-linked muropeptides and an increase in the average length of the peptidoglycan chains. These changes were associated with a statistically significant fitness cost, which was demonstrated both in vitro and in vivo in a mouse model of systemic infection (34) (Fig. 1). The biological cost associated with these changes indicates the importance of the interaction between β-lactamases and peptidoglycan metabolism. Determination of the biological cost may also provide information about the epidemiology of β-lactamases and help explain the low incidence of some of these enzymes in specific pathogens, such as E. coli. A similar example of the effect of β-lactamases on fitness cost in Enterobacteriaceae is provided by the expression of AmpC of Salmonella enterica (35), which was associated with reduced growth rate and invasiveness, although the authors did not observe any major variations in the peptidoglycan composition of this microorganism.

Fig 1
  • Open in new tab
  • Download powerpoint
Fig 1

Data from in vitro competition experiments with E. coli MG1655 carrying the recombinant plasmids pBGS18-TEM1, pBGS18-SFO1, pBGS18-AmpR-SFO1, pBGS18-OXA10-like, pBGS18-FOX4, and pBGS18-CTX-M-32. The strains expressing AmpR-SFO1, OXA10-like, and OXA24 β-lactamases showed significant fitness costs. The CI values obtained with different β-lactamases are plotted and are representative of eight different experiments, with the median CI values shown by horizontal lines. (Adapted from reference 34.)

Extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strains have been suggested to possess higher pathogenic potential than nonproducers. Sahly et al. examined the ability of 58 ESBL-producing and 152 nonproducing isolates of K. pneumoniae to express type 1 and 3 fimbrial adhesins, which are important traits in microbial adherence and invasion of host cells (36). Although the adherence of ESBL- and non-ESBL-producing strains to epithelial cells did not differ significantly (P > 0.05), the proportion of strains able to invade (>5% relative invasion) ileocecal and bladder epithelial cells was significantly higher among ESBL producers (81% and 27.6%, respectively) than among non-ESBL producers (61% and 10%, respectively). Likewise, the proportion of ESBL producers coexpressing both fimbrial adhesins was significantly higher than that of non-ESBL producers. On acquisition of the ESBL SHV-12-encoding plasmids, two transconjugants started to produce type 3 fimbriae, although expression of type 1 fimbriae was not affected. Overall, the data demonstrated that an ESBL plasmid appeared to upregulate the expression of one or more genes, resulting in a higher invasion capacity. It remains unclear whether this effect resulted from direct SHV-type expression or expression of another plasmid-borne gene.

Another interesting example is the role of ampC expression and its impact on fitness or virulence in P. aeruginosa. In 2008, Moya et al. reported that inactivation of ampD in P. aeruginosa led to a partially derepressed phenotype, characterized by a moderately high level of ampC expression, which could be induced even further due to the presence of two additional ampD genes (ampDh2 and ampDh3). Sequential inactivation of these genes resulted in full derepression in the triple mutant, which exhibited 1,000-fold overexpression of the ampC gene relative to the wild-type isogenic strain, thus causing a loss of virulence due to alterations in peptidoglycan recycling (10). Due to this multiplicity of ampD genes, fitness costs and virulence are scarcely affected in P. aeruginosa, despite increases in β-lactam MICs, so that this bacterium is able to develop resistance to β-lactam antibiotics without a significant loss of fitness. Only ampDh3 was found to be important for virulence in P. aeruginosa. In this example, resistance and virulence are chromosomally regulated, showing how the multiplicity of ampD genes may constitute a regulatory mechanism for the ampC gene (β-lactam resistance) and maintenance of the cell wall (thus affecting virulence).

In Enterobacteriaceae and P. aeruginosa, the transcriptional regulator AmpR, a member of the LysR family, regulates the expression of a chromosomal β-lactamase, AmpC. However, AmpR appears to have a wider physiological role in these organisms because, in addition to regulating expression of ampC, AmpR regulates the expression of sigma factor AlgT/U (alginate production) and production of some quorum-sensing (QS)-regulated virulence factors (37, 38). The authors compared DNA microarrays of the P. aeruginosa PAO1 strain and its isogenic ampR deletion mutant PAO ΔampR, and they found that AmpR regulates AmpC expression (resistance to β-lactams) and also non-β-lactam antibiotic resistance by modulating the MexEF-OprN efflux pump (37, 38). This is a good example of how such organisms may simultaneously regulate antibiotic resistance in addition to biofilm formation and QS-regulated acute virulence factors. Similarly, AmpR has been found to upregulate capsule synthesis (and, therefore, resistance to serum killing) and to modulate biofilm formation and type 3 fimbrial gene expression in a clonal strain of K. pneumoniae producing the plasmid-encoded cephalosporinase DHA-1 (39), which suggests that AmpR may regulate several virulence factors in addition to ampC expression.

It appears to be of great interest to study this effect with the nosocomial pathogen A. baumannii, in which the main mechanism involved in carbapenem resistance is the production of OXA-type β-lactamases (40). Although the involvement of these enzymes in resistance to β-lactams (specifically carbapenems) is a cause of great concern, very few studies have addressed the impact of these enzymes on the virulence of A. baumannii. Sechi et al. investigated the presence and association of various virulence determinants in 20 A. baumannii isolates, 13 of which were bla PER-1 positive (41). These authors found a relationship between PER-1 and cell adhesion in Acinetobacter strains, although the exact mechanisms of the association remain unknown. In A. baumannii, OXA-24 is one of the main enzymes involved in carbapenem resistance, at least in some countries (42, 43). One of the most striking features of this enzyme, and of all OXA-type enzymes in general, is its scarce presence in Enterobacteriaceae.

In February 2006, a patient colonized with an MDR A. baumannii sequence type 56 (ST56) strain (updated in the new multilocus sequence type [MLST] database as ST121) was admitted to a hospital in Madrid, Spain. The strain spread very quickly and caused the largest nosocomial outbreak ever reported in the literature (377 patients were colonized/infected with A. baumannii; of these, 290 were colonized/infected with antibiotype 1 associated with an MDR clone, AbH12O-A2) (44). A. baumannii clone AbH12O-A2 exhibited a broad antimicrobial drug resistance profile, was resistant to carbapenems, and showed susceptibility only to tigecycline and colistin. One of the main characteristics of this strain was its capacity to produce invasive infections (the annual incidence of A. baumannii-induced bacteremia increased from 0.03 episodes/100,000 bed days in 2002 to 1.1/100,000 bed days in 2007, which corresponded to the peak of the outbreak caused by clone AbH12O-A2). The plasmid isolated from this epidemic strain was named pMMA2. Sequencing of nucleotides revealed the presence of the carbapenemase OXA-24 (42) flanked by XerC/XerD binding sites. The genes for two putative plasmid-encoded virulence factors, septicolysin and TonB-dependent receptor, were also found surrounding the bla oxa-24 gene. The first of these was a cholesterol-dependent cytolysin and has been reported to be produced by pathogenic bacteria such as Clostridium perfringens, Bacillus anthracis, and S. pneumoniae (45). The TonB-dependent receptor gene has been associated with virulence and iron uptake in A. baumannii (46). Analysis of the structure of this pMMA2 plasmid (Fig. 2A) is of interest and provides information about how this MDR clone has been selected, possibly by a putative coevolution process in which a carbapenem resistance gene plus two putative virulence factors may facilitate its persistence and virulence in the hospital setting. In this case, resistance and virulence coexist in the same bacterium to yield a highly successful microorganism that is able to cause very serious infections in hospital settings.

Fig 2
  • Open in new tab
  • Download powerpoint
Fig 2

Partial structures and descriptions of different plasmids carrying virulence factors and antimicrobial resistance determinants together. Light gray, virulence genes; dark gray, antimicrobial resistance genes; black, plasmid maintenance genes. (A) Plasmid pMMA2, isolated from clinical isolate AbH12O-A2, which caused a large nosocomial outbreak. (Adapted from reference 436.) (B) Plasmid pEK499, which carries up to 10 resistance genes, including the genes encoding resistance to β-lactamases (bla TEM-1, bla CTX-M-15, and bla OXA-1), aminoglycosides (aac6-Ib-cr), macrolides [mph(A)], chloramphenicol (catB4), tetracycline [tet(A)], streptomycin (aadA5), and sulfonamide (sulI). It possess two copies of the vagD-vagC virulence-associated system and the toxin/antitoxin pemI-pemK and ccdA-ccdB systems, which are involved in plasmid maintenance by postsegregation killing processes. (Reprinted from reference 229.) (C) Plasmid pRSB107, which carries genes encoding resistance to the following antibiotics: β-lactams (bla TEM-1), aminoglycosides (aph), streptomycin (strA-strB), sulfonamide (sulI), macrolides [mph(A)], trimethoprim (dhfR), chloramphenicol (catB4), and tetracycline [tet(A)]. This plasmid carries four putative virulence-associated determinants: an aerobactin iron acquisition siderophore system (iucA, iucB, iucC, iucD, and iutA), a putative high-affinity Fe2+ uptake system (orf82), an sn-glycerol-3-phosphate transport system (ugpB, ugp, ugpE, and ugpA), and two copies of the virulence-associated genes vagC-vagD. Approx., approximately. (Reprinted from reference 237.)

Permeability and porins.Porins are β-barrel membrane proteins that cross cell membranes and act as a pore through which molecules, such as nutrients, toxins, and antibiotics, can diffuse. Alterations, modification, and reduction in the expression of porins have all been associated with antimicrobial resistance to some extent (47). Porins have a clear role in virulence and resistance. We emphasize studies involving A. baumannii (OmpA, Omp33-36, CarO, and OprD-like porins) and Enterobacteriaceae (OmpC/OmpF and OmpK35/OmpK36 porins), as shown in Table 1.

It is assumed that bacterial outer membrane proteins with a porin function not only control the entry of antimicrobials into bacterial cells but also control the virulence of the microorganism. The A. baumannii OmpA protein has recently been associated with resistance to cephalothin and cephaloridine in A. baumannii (48). Indeed, it has been reported that OmpA porin induces death of epithelial and dendritic human cells through mitochondrial targeting (49) and is also involved in biofilm formation (50, 51). Another two porins, CarO and Omp33-36, have been associated with carbapenem resistance in this species (52, 53). Other porins (such as OprD), initially associated with resistance to carbapenems, have recently been associated with other physiological functions (similarly to the OprQ-like protein of P. aeruginosa), and it is possible that they contribute to the adaptation to magnesium- and/or iron-depleted environments (54). Fernandez-Cuenca et al. demonstrated attenuated virulence of a slow-growing pan-drug-resistant A. baumannii strain associated with decreased expression of genes encoding the CarO and OprD-like porins (55). The Omp33-36 protein of A. baumannii, which is involved in carbapenem resistance, has also been suggested to be involved in apoptosis and modulation of autophagy processes (unpublished data). Moreover, Cabral et al. recently reported the involvement of both CarO and Omp33-36 porins in biofilm formation in A. baumannii (51). Both OmpA and Omp33-36 proteins and also the TonB-dependent copper receptor have recently been identified as fibronectin-binding proteins (FBPs) and as being involved in the interaction between this pathogen and fibronectin, thus furthering the understanding of A. baumannii adherence to host cells (56).

In E. coli, the loss of OmpC contributes to both antibiotic resistance and reduced antibody-dependent bactericidal activity (57). Moreover, the OmpC protein has been associated with adhesion, cell invasion, and intestinal colonization in patients with Crohn's disease (58). Bekhit et al. demonstrated that both OmpC and OmpF (both of which are involved in antimicrobial resistance) are essential for the survival of E. coli under extremely acidic conditions (59). OmpF has also been associated with adhesion to Hep-2 cells (60). The OmpK35 and OmpK36 outer membrane porins of K. pneumoniae are involved in resistance to cefazolin, cephalothin, and cefoxitin and increased meropenem and cefepime MICs. A significant (P < 0.05) increase in the susceptibility to phagocytosis was detected in both ΔOmpK36 and ΔOmpK35/36 mutants. In a mouse peritonitis model, the ΔOmpK36 mutant also exhibited significantly lower virulence, whereas both mutants together presented the highest median lethal dose (LD50) of these strains. Overall, these data suggest that porin deficiency in K. pneumoniae may increase antimicrobial resistance while simultaneously decreasing virulence. Similar findings have been described for other members of Enterobacteriaceae and for Neisseria meningitidis, P. aeruginosa, and Vibrio spp. (61 – 64).

Overall, the data strongly suggest a role for outer membrane proteins (porins) in microorganism virulence, as well as in resistance to β-lactams and other antibiotics. Therefore, the acquisition of a phenotypic advantage such as antimicrobial resistance is linked to a deleterious effect on bacterial survival in various hosts and ecological niches.

Efflux pumps.Multidrug efflux pumps of bacterial pathogens are involved in intrinsic and acquired resistance to antimicrobial compounds, including those naturally present at mucosal surfaces; the pumps enable bacteria to grow on such surfaces and can thus be considered as being involved in colonization (65). Moreover, multidrug efflux pumps can discharge molecules involved in the quorum-sensing-regulated expression of virulence determinants (66). Efflux pumps have also been shown to be important for detoxification of intracellular metabolites and are involved in bacterial virulence (in both animal and plant hosts), as well as cell homeostasis and intercellular signal trafficking. Drug efflux can be driven by a proton gradient (such as resistance-nodulation-division [RND], small multidrug resistance [SMR], multidrug and toxic compound extrusion [MATE], and major facilitator superfamily [MFS] transporters) or by energy derived from ATP hydrolysis (ATP-binding cassette [ABC]) (Fig. 3) (67).

Fig 3
  • Open in new tab
  • Download powerpoint
Fig 3

Functional role of bacterial multidrug efflux pumps in natural microbial ecosystems. (Reprinted from reference 67 with permission from John Wiley and Sons.)

Some efflux pumps, especially those in the RND family, have been shown to play a role in the pathogenicity of bacteria, mainly affecting colonization, infection, and the persistence of microorganisms in the host (68). Among Enterobacteriaceae and other Gram-negative rods, the involvement of the AcrAB-TolC efflux pump in antimicrobial resistance (including resistance to β-lactams, tigecycline, and others) and virulence has been extensively studied in species of clinical importance, including E. coli, K. pneumoniae, S. enterica serovar Typhimurium, Enterobacter aerogenes, Enterobacter cloacae, Vibrio cholerae, Francisella tularensis, Burkholderia pseudomallei, P. aeruginosa, Proteus mirabilis, and Brucella spp. (69 – 85), as well as nonpathogenic microorganisms such as Ralstonia solanacearum and Erwinia spp. among others (86, 87). The ability of bacterial pathogens to colonize, infect, and cause disease depends on their capacity to resist antibiotics, antimicrobial compounds produced by the host (such as bile acids, fatty acids, and other detergent-like molecules), and also components of the immune system (e.g., antimicrobial peptides). Clearly, such resistance may be mediated by active efflux systems belonging to the RND family of transporters, which can extrude antimicrobial agents as well as the plethora of different compounds described above. Therefore, abrogation of efflux mechanisms undoubtedly affects both virulence and resistance to antibiotics in clinical practice, in terms of colonization and host infection, although there are some remarkable exceptions, such as AcrAB-TolC in Yersinia pestis, as in a mouse plague model, pump deletion did not have a significant effect on tissue colonization (88). However, the impact of individual AcrAB-TolC components has been evaluated in competition experiments (to measure fitness). As indicated in Fig. 4, deletion of either acrA or tolC in two different E. cloacae strains (each hyperexpressing AcrAB-TolC or expressing them at basal level) has a clear impact on fitness (measured in vitro and in vivo) (89). In this family, efflux pumps are also required for the colonization and persistence of bacteria in the host, whether plants, animals, or humans.

Fig 4
  • Open in new tab
  • Download powerpoint
Fig 4

Results of in vivo competition experiments in a mouse model of systemic infection (median CI values are shown by horizontal lines). The figure reflects the competition index values of the acrA and tolC efflux pump component mutant strains compared with the wild-type EcD64 and JC194 E. cloacae clinical isolates. Decreased fitness is observed when the efflux system is inactivated. (Adapted from reference 89.)

One study has shown that the virulence of S. enterica lacking a component of AcrAB-TolC becomes attenuated and that this phenotype is the result of decreased expression of genes involved in pathogenicity, including those required for anaerobic growth, motility, and host cell invasion (79). This is an important example that establishes a link between antibiotic resistance and AcrAB-TolC-mediated virulence in S. enterica. Padilla et al. also showed that a K. pneumoniae acrAB knockout mutant exhibited a lower capacity than the wild-type strain to cause pneumonia in a murine model (90). Bialek et al. found that overexpression of the AcrAB efflux system in the Caenorhabditis elegans model is linked to an increased virulence potential in K. pneumoniae (91). Overall, these studies emphasize that the expression of efflux systems is a key factor in both antibiotic resistance and virulence in K. pneumoniae. Similarly, a V. cholerae strain null for the RND efflux pump showed impaired production of cholera toxin and fewer toxin-coregulated pili relative to those in the wild type (due to reduced transcription of tcpP and toxT [76]), and it was thus unable to colonize the infant mouse.

The MexAB-OprM system of P. aeruginosa is constitutively expressed in almost all isolates, and substrates for this pump include fluoroquinolones, tetracycline, chloramphenicol, and β-lactams (92, 93). Of the various multidrug efflux pump determinants characterized in P. aeruginosa to date, epidemiological analysis has demonstrated that mutants with enhanced expression of mexAB-oprM (nalB mutants) or mexCD-oprJ (nfxB mutants) are the most frequently encountered among clinical isolates (94). Various studies linking efflux pumps to virulence in this species have produced controversial results. Overproduction of the multidrug efflux pump determinants MexAB-OprM and MexCD-OprJ has been associated with decreased survival in water, production of phenazines and proteases, and virulence (94). Linares et al. studied P. aeruginosa strains in which overproduction of either MexCD-OprJ or MexEF-OprN was associated with a reduction in the transcription of the type III secretion system (TTSS) regulon due to the lack of expression of the exsA gene, which encodes the master regulator of the type III secretion system (95, 96). Finally, a multidrug-resistant P. aeruginosa strain with enhanced virulence, designated the “Liverpool epidemic strain” (LES), has recently been described in cystic fibrosis (CF) patients from the United Kingdom (97). This work identified an isolate, LES431, with high levels of β-lactamase activity coupled with upregulation of QS-regulated virulence genes, which because of its history might be considered a highly virulent variant of the clone. Moreover, this strain is characterized by upregulation of the MexAB-OprM efflux pump in relation to resistance to β-lactam antibiotics, and in contrast to the above-described case, it shows greater virulence than the wild-type strain (this issue will be discussed below) (98, 99). Therefore, it appears that other factors in addition to efflux pump upregulation are involved in modulating the virulence of P. aeruginosa.

The GacA/RsmA/RsmB (RsmZ) signal transduction system is a conserved pathway involved in a variety of adaptive functions in P. aeruginosa. RsmA has numerous homologs in both Gram-negative and Gram-positive bacteria. Loss of RsmA alters the expression of genes involved in a variety of pathways and systems that are important for virulence, including iron acquisition, biosynthesis of the Pseudomonas quinolone signal, and the formation of multidrug efflux pumps and motility. Loss of rsmA results in increased expression of the genes encoding the MexEF-OprN pump. In P. aeruginosa, the MexEF-OprN pump has been found to extrude numerous antibiotics and Pseudomonas quinolone signal from the cell. Thus, levels of mexS mRNA, which encodes a transcriptional repressor of MexEF-OprN, were four times higher in the rsmA mutant than in PAO1, which reflects the complexity of Mex pump regulation (100). In addition to its role in resistance to antibiotics, the MexEF-OprN efflux pump is an important system that modulates the virulence of P. aeruginosa through the export of specific quorum-sensing (QS) regulatory molecules, especially 4-hydroxy-2-heptylquinoline (HHQ) (101). Different bacterial virulence factors are regulated by QS, thus highlighting the great potential of this system to attenuate microbial virulence. Moreover, hyperexpression of the MexAB-OprM multidrug efflux system results in reduced levels of several extracellular virulence factors known to be regulated by QS. Autoinducers (AIs) are a family of acylated homoserine lactones found in a number of Gram-negative bacteria, accumulation of which in the growth medium controls cell density and triggers expression of specific genes after reaching a critical concentration (66). After entering cells, the AI (with the aid of a transcriptional activator) activates target genes in response to increased bacterial cell density. Two homoserine lactone AIs (PAI-1 and PAI-2) have been characterized in P. aeruginosa, which, together with their QS regulators, LasR and RhlR, act to stimulate production of a number of extracellular virulence factors in P. aeruginosa. Importantly, reentry of PAI-1 is reduced by the efflux activity of P. aeruginosa pumps, which leads to a reduction in the expression of PAI-1-dependent genes (including virulence factors). This MexAB-OprM mechanism constitutes a link between increased antimicrobial resistance and decreased QS-mediated virulence in P. aeruginosa (66, 102).

The SecDF system has been studied in E. coli, Bacillus subtilis, and S. aureus. In S. aureus, the SecDF system has been associated with impaired cell division, reduced resistance to the β-lactam oxacillin and to the glycopeptide vancomycin, and altered expression of virulence genes (atl, coa, hla, hld, and spa) (103).

Resistance to Aminoglycosides and Effect on VirulenceAminoglycosides are used to treat a wide range of infections caused by both Gram-negative and Gram-positive bacteria. The mechanism of action is related to binding to the A site of the 16S rRNA, which forces A1492 and A1493 to “flip out” of helix 44 (104). This ribosome interaction leads to a loss of translational fidelity and thus to the accumulation of erroneous proteins and bacterial cell death. Resistance to aminoglycosides is usually due to production of aminoglycoside-modifying enzymes (acetyltransferases [AACs], phosphoryltransferases [APHs], and adenyltransferases [ANTs]), reduced intracellular antibiotic accumulation (by outer membrane alterations, two-component systems or efflux pumps), or mutation of ribosomal proteins or RNA (105). Methylation of the aminoacyl site of 16S rRNA also confers a high level of resistance to clinically important aminoglycosides, such as amikacin, tobramycin, and gentamicin. This event is mediated by a group of 16S rRNA methyltransferases. Six acquired 16S rRNA methyltransferase genes confer resistance to aminoglycosides, namely, armA, rmtA, rmtB, rmtC, rmtD, and rmtE.

Aminoglycoside-modifying enzymes.Although no direct relationship between virulence and resistance has been found, aminoglycoside resistance genes (encoding AACs, APHs, or ANTs) are often located in different MGEs, such as integrons and plasmids (106 – 108). These genes are therefore usually coselected with other antibiotic resistance genes, such as those encoding β-lactamases.

Efflux pumps.Expression of efflux pumps is usually associated with increased MICs of the clinically used aminoglycosides (amikacin, gentamicin, or tobramycin). Examples include efflux pumps belonging to the RND family, such as AcrAB-TolC of E. cloacae (109), AdeABC of A. baumannii (110), or MexXY of P. aeruginosa (105). The impact of efflux pump expression on virulence is described above in the section on β-lactams and resistance conferred by efflux pumps. Thus, the previous discussion can also be applied to aminoglycosides.

Ribosomal methylases.In microorganisms, ArmA/Rmt methyltransferases have recently been found to cause a high level of resistance to 4,6-disubstituted aminoglycosides through methylation of the G1405 residue in 16S rRNA (such as ArmA and RmtA to -E). In prokaryote ribosomes, methylation of rRNA is necessary to optimize ribosomal function, so that prokaryotic microorganisms harbor housekeeping methyltransferases in order to modulate this function. In E. coli, the RsmF housekeeping methyltransferase methylates at C1407, a nucleotide that is very close to G1405 (the position of RmtC methylation) and that forms part of the same aminoglycoside-binding pocket of the 16S rRNA. By using a series of isogenic E. coli mutants, Gutierrez et al. showed that acquisition of RmtC does not have a fitness cost for the bacterium: coupling between housekeeping and acquired methylases subverts the methylation architecture of the 16S rRNA and favors selection of Arm/Rmt methyltransferases, thus constituting a potential threat when microorganisms are treated with aminoglycosides (104).

Ribosomal mutations.The tendency of aminoglycoside-resistant bacteria to have a competitive disadvantage in an environment free of antibiotics may be related to the nature of the resistance mechanism. For instance, numerous types of resistance that are mediated by chromosomal mutations result from target alterations. If this occurs, the final fitness cost may become apparent if the target alterations associated with the resistance phenotype display suboptimal functionality, as shown for mutations in the gene rpsL, which confers resistance to streptomycin and other aminoglycosides in E. coli, Salmonella spp., and Gram-positive bacteria, including Mycobacterium tuberculosis (13, 111 – 115). Acquired gentamicin resistance mediated by permeability changes in Enterococcus faecalis has been described, although the impact on virulence was not evaluated (116).

In conclusion, although chromosomal mutations that result in ribosomal alteration and resistance affect fitness, they will probably be selected in microorganisms only under high aminoglycoside pressure. This would explain why this mechanism is not often identified in the clinical setting. Thus, microorganisms will be selected by other antimicrobial resistance mechanisms with a lower fitness cost, such as aminoglycoside-modifying enzymes, which cannot yield any fitness cost in the absence of antibiotic pressure.

Resistance to Fluoroquinolones and Effect on VirulenceSeveral mechanisms of resistance to quinolones have been described: target modification (topoisomerase and DNA gyrase mutations), efflux pumps, Qnr (plasmid-mediated gene encoding quinolone resistance), porins, and quinolone-modifying enzymes (117). The primary targets of quinolones differ in Gram-negative and Gram-positive bacteria (DNA gyrase and topoisomerase IV, respectively). Modifications to both targets result in resistance to quinolones. As mentioned above, multidrug efflux pumps are involved in resistance to different antibiotics, including quinolones. Nonetheless, the widespread presence of plasmid-mediated quinolone resistance determinants, particularly qnr genes, has become apparent. In the worldwide clone of E. coli 025-ST131, plasmids harboring different quinolone-resistance genes have been reported; these include qnrB2 and aac(6′)-Ib-cr (118). Another mechanism involved in resistance to quinolones is a decrease in the expression of outer membrane proteins (porins). So far, there are no reports relating quinolone-modifying enzymes to virulence.

Target modification (topoisomerase and DNA gyrase mutations).The cost of quinolone resistance caused by topoisomerase mutations has been studied in P. aeruginosa, Salmonella spp., Shigella flexneri, E. coli, and A. baumannii (Table 1). Kugelberg et al. analyzed P. aeruginosa norfloxacin-resistant mutants and showed that “no-cost” and compensatory mutations are common in quinolone-resistant P. aeruginosa with mutations in topoisomerase. The authors commented on the significance of these mutations for the persistence of bacteria resistant to quinolones and established the importance of implementing strategies for treating and preventing the spread of resistant strains before they become stable bacterial populations (119). In contrast, the high level of resistance to ciprofloxacin in in vitro-derived mutants of S. enterica is associated with fitness costs. In the absence of evidence of compensatory evolution, such fitness costs may account for the lack of emergence and spread (to date) of highly resistant S. enterica clones via the farm-to-fork route (120). Moreover, quinolone-resistant Salmonella spp. usually contain chromosomal point mutations that result in alterations of the A subunit of DNA gyrase. Similar findings have been reported for ciprofloxacin resistance in A. baumannii showing mutations in topoisomerase and DNA gyrase (121, 122). However, with strains of S. Typhimurium that are resistant to nalidixic acid, infection was found to be associated with a 3.15-fold risk of invasive illness or death within 90 days of infection compared with that observed for infection with pansusceptible strains (123), which revealed apparently contradictory results. Other Enterobacteriaceae species (e.g., Shigella flexneri) that overexpress topoisomerase IV genes can compensate for the loss of topoisomerase I in terms of DNA supercoiling, virulence gene expression (partially), and cell viability in general (124). Finally, E. coli resistant to ciprofloxacin due to parC and gyrA mutations showed no decreases in in vitro or in vivo growth rates (125). The biological cost of quinolone resistance differs between bacterial species and depends on the level of resistance and the number of resistance mutations, and highly resistant mutants with multiple mutations show a significantly lower level of fitness than the wild-type strains. However, for low-level-resistant mutants with single mutations, the cost depends on the bacterial species.

In strains of P. aeruginosa, mutations in gyrA at codon Ile83Thr and in parC at codon Leu87Ser have been associated with expression of the type III secretion system (TTSS) genes (exoS, exoT, exoU, and exoY), which are involved in virulence (126). In another study of infections caused by clinical strains of P. aeruginosa, fluoroquinolone resistance and type III secretion system virulence were independently associated with poor patient outcome. The observed positive relationship between fluoroquinolone resistance, carriage of exoU (encoding a cytotoxin), and enhanced cytotoxicity suggests that adverse outcomes related to fluoroquinolone-resistant P. aeruginosa infections may be attributable to associated enhanced TTSS-mediated virulence. The results of this study suggest coselection of fluoroquinolone resistance and enhanced TTSS-mediated virulence in P. aeruginosa clinical isolates harboring exoU (127). Finally, in a recent study, Agnello and Wong-Beringer emphasized concern about the problem in the near future in regard to the coevolution of resistance to quinolones (mutations in gyrA, gyrB, parC, and parE) and increased virulence (expression of ExoU and ExoS), which will favor the development of virulent genotypes, particularly in quinolone-rich environments (128).

Studies of Gram-positive bacteria have focused mainly on S. aureus and S. pneumoniae. Several studies have associated the resistance of S. aureus to ciprofloxacin (mutations in DNA gyrase) with the sarA gene regulator (see “Alternative Sigma Factor σB” below) (129, 130). However, the use of subinhibitory concentrations of ciprofloxacin to treat infections caused by S. aureus strains not only selects for highly resistant strains but also induces the production of virulence factors such as fibronectin-binding proteins, which may promote persistent infection among drug-resistant survivors (131). In a comparison between isogenic quinolone-resistant (IQR) isolates of S. pneumoniae and their fluoroquinolone-susceptible parents with mutations in GyrA (Ser81Phe) and ParC (Ser79Phe), the relative growth efficiencies revealed a reduction in nasal colonization for the resistant isolates during competitive or noncompetitive lung infections. Moreover, isogenic quinolone resistance may have reduced ability to initiate infections in the absence of fluoroquinolone selection. This suggests that the correct use of antimicrobial drugs may maintain the prevalence of IQR clones at low levels because of the relatively low fitness of these clones (132).

Efflux pumps.Efflux pump systems have been studied in relation to β-lactam resistance, and the results can be extrapolated to quinolone resistance. However, in this section we discuss some specific examples of efflux pumps involved in quinolone resistance and virulence, such as the already-described AcrAB-TolC (Enterobacteriaceae) and Mex (P. aeruginosa) systems, as well as MgrA (a global regulator of the NorA, NorB, NorC, Tet38, and AbcA efflux pumps in S. aureus), BepDE (Brucella suis), and SmeDEF (Stenotrophomonas maltophilia), which will be described here and summarized in Table 1.

Study of the relationship between efflux-mediated resistance and virulence of S. aureus can be addressed by analysis of global regulators such as the MgrA type, which is a homolog of MarR and SarA and is involved in regulation of the expression of α-hemolysin, protein A, lipase, protease, and coagulase, which are virulence gene products as well as autolysins, and type 8 capsular polysaccharide. Moreover, multidrug resistance efflux transporters such as NorA, NorB, NorC, Tet38, and AbcA, which are involved in resistance to quinolones, are controlled by the MgrA regulator (133).

Two functional RND efflux pumps that may contribute to virulence have been studied in Brucella suis. Specifically, there are two membrane fusion protein-RND translocases of B. suis, encoded by the bepDE and bepFG loci. The resistance profile of B. suis in the presence of multicopy bepDE indicates that BepDE is able to extrude antibiotics, including tetracycline, doxycycline, and fluoroquinolones. Only the BepFG-defective mutant showed moderate attenuation in in vitro assays with HeLa cells, and the activities of both bepDE and bepFG promoters were induced in the intracellular environment of HeLa cells (134).

The SmeDEF efflux pump has been studied in Stenotrophomonas maltophilia showing resistance to quinolones and erythromycin (135). Overexpression of the system in this bacterium was associated with decreased fitness as well as a decline in cell size when isolates were grown in a rich medium (136).

Qnr proteins.The plasmid-mediated qnr genes products are pentapeptide repeat proteins, which lead to quinolone resistance. The mechanism of action, which is based on protection of DNA gyrase and topoisomerase IV, has been studied in great detail in strains with the qnrA1 gene and is presumably similar to the mode of action of other Qnr proteins (117, 137). Michon et al. determined the effect of qnr acquisition on fitness by examining in vitro growth curves and studying in vitro pairwise competition and in vivo single culture and pairwise competition (138). These authors concluded that plasmidic qnrA3 enhances Escherichia coli fitness in the absence of antibiotic exposure, thus favoring its possible spreading.

Porins.The role of porins in binomium resistance/virulence has already been discussed in the section on resistance to β-lactams, and the conclusions can be extrapolated to fluoroquinolones.

Resistance to Tetracyclines and Tigecycline and Effect on VirulenceTetracyclines are bacteriostatic antibiotics that bind reversibly to the ribosome 30S subunit, thereby inhibiting the initiation of protein synthesis; these antibiotics enter bacterial cells by passive diffusion or by active transport. The main resistance mechanisms are efflux systems encoded by the tet genes, such as tetA and tetB (also involved in virulence), although other mechanisms of resistance to tetracyclines have been described, such as ribosomal protection and antibiotic modification (tetX) (139). Although studies investigating links between tetracycline resistance mechanisms and virulence/fitness are scarce, here we report some examples of the main mechanisms of resistance to tetracyclines involved in virulence (summarized in Table 1).

Efflux pumps.As the Tet efflux systems are monocomponent, structurally different from the RND efflux family, and specific for tetracyclines, they are discussed separately. A study in the absence of selective pressure was performed in infants during the first year of life. Although the children were not exposed to tetracycline, resistance to this antibiotic was detected in 12% of the strains of E. coli collected, all of them with tetA or tetB genes encoding efflux pumps. The tetA- and tetB-positive strains carried the virulence genes for P fimbriae and aerobactin, respectively, more often than the susceptible strains. However, strains that were resistant and susceptible were simultaneously isolated from 11 of the children; the tetracycline-resistant strains were present in significantly lower numbers, which indicated reduced fitness (140). In this example, it can be seen that even in the absence of antibiotic pressure (tetracyclines), a high percentage of strains express resistance mechanisms and different virulence genes. However, this genetic burden involves a certain fitness cost. Although it is not clear why the tetracycline-resistant strains carried P fimbria and aerobactin genes more often than the susceptible strains, the authors hypothesized that these genes increase the persistence of E. coli in the intestinal microbiota, thus increasing the possibility of contact between the bacteria and the antibiotic, and then selection of resistant strains.

Tet efflux pumps also can be transported in MGEs, such as tetG in Salmonella genomic island 1 (SGI1), which contains 6 to 9 virulence determinants and a multidrug resistance region that confers resistance to tetracyclines (and other antimicrobials). Because of their repertory of resistance and virulence genes, these types of isolates may become clinically relevant (141).

Ribosomal protection.Few studies have investigated resistance due to ribosomal modifications and virulence. The tet(44) gene, which has been reported to be involved in resistance in Campylobacter fetus, is located in a pathogenicity island (PAI) that encodes the components necessary for the bacterial type IV secretion system (142) showing a coselection phenomenon.

In Helicobacter pylori, resistance to tetracycline is uncommon and is due to the accumulation of changes that affect ribosome affinity (mutations in the 16S rRNA gene) and possibly to other functions such as efflux systems and decreased expression of porins. Dailidiene et al. suggested that the rare tetracycline resistance in H. pylori is probably due to these multiple mutations with deleterious effects on fitness and the accumulation of many defective functions (143).

Antibiotic modification.In addition to efflux and ribosomal protection, there is a third resistance mechanism, i.e., the modification or inactivation of tetracyclines by one of the flavin-dependent monooxygenases encoded by the tetX, tet(34), and tet(37) genes, which have similar proprieties. The tetX gene, which was found in an isolate of the anaerobe Bacteroides fragilis, confers resistance when it is transformed in E. coli; however, so far this mechanism has not been found in any clinical isolates (144, 145). No studies of tetX and its fitness/virulence cost have been published to date, but the absence of other clinical pathogens with this mechanism indicates that its expression may have a significant cost in Gram-negative aerobes.

Tigecycline.Tigecycline is one of the glycylcyclines, a new class of antimicrobials derived from tetracyclines. Mechanisms of tigecycline resistance, such as the RND efflux system, also provide resistance to tetracyclines. Although tigecycline remains more active than other antimicrobials usually tested against MDR pathogens (e.g., fluoroquinolones and β-lactams), several tigecycline-resistant strains have been described in recent years (146).

P. aeruginosa, P. mirabilis, and Morganella morganii are intrinsically resistant to tigecycline because of the expression of RND family transporters such as MexAB-OprM, MexCD-OprJ, and AcrAB (83, 85, 147). Upregulation of the AcrAB efflux system, which confers tigecycline resistance, has been described in E. coli, K. pneumoniae, and E. cloacae (81, 82, 84), and the AdeABC efflux appears to be involved in tigecycline resistance in A. baumannii (148, 149) (Table 1). Thus, the increased resistance to tigecycline mediated by efflux systems will be directly involved in changes in the bacterial virulence, as reviewed in “Efflux pumps” above.

Resistance to Macrolides and Effect on VirulenceIn Gram-negative bacteria, resistance to macrolides is associated mainly with the overexpression of efflux pumps. However, in Gram-positive pathogens, resistance to macrolides has been associated with efflux pumps (mef class genes), which confer a phenotype of low-level resistance, and alteration of the target site by ribosomal methylation (erm class genes), which is involved in high-level resistance to all macrolides, lincosamides, and streptogramin B (122).

Efflux pumps.Three efflux pumps have been associated with macrolide resistance and with virulence mechanisms: MuxABC-Omp in P. aeruginosa, BpEAB-OprB in Burkholderia pseudomallei KHM, and MtrC-MtrD-MtrE in Neisseria gonorrhoeae (Table 1).

Recently, the MuxABC-Omp system has been shown to play a role in resistance to novobiocin, aztreonam, macrolides, and tetracycline in a laboratory mutant of P. aeruginosa (150). Inactivation of muxA in the muxABC-ompB operon showed attenuated virulence associated with decreased twitching motility and elevated resistance to ampicillin and carbenicillin (151).

The BpEAB-OprB system has been reported to act as an efflux pump for aminoglycosides and macrolides in B. pseudomallei strain KHM (from Singapore) and to play an important role in virulence and quorum sensing. This efflux pump was also required for optimal production of biofilms, siderophores, and phospholipase C; the excretion of acyl homoserine lactones (AHLs) (quorum-sensing molecules), also depended on BpeAB-OprB function (80, 152). However, Mima and Schweizer obtained different results with B. pseudomallei strain 1026b (153). These authors concluded that BpeAB-OprB does not mediate efflux of aminoglycosides but that it extrudes other antibiotics, including fluoroquinolones, clindamycin, macrolides, and tetracyclines. On the other hand, BpeAB-OprB mutants were not impaired in extrusion of acyl homoserine lactones, swimming motility, or siderophore production, but AmrAB-OprA and BpeAB-OprB mutants were impaired in biofilm formation (153).

The MtrC-MtrD-MtrE efflux pump system of N. gonorrhoeae is also involved in virulence and resistance to antibiotics. In an experimental gonococcal genital tract infection, derepression of the mtrCDE operon, via deletion of mtrR, was found to confer increased fitness in vivo and increased the antimicrobial resistance in vitro (154).

Ribosomal methylation and modification.Two mechanisms of macrolide resistance based on methylation ribosomal have been studied in relation to virulence: the erm gene and 23S rRNA mutations (Table 1).

Regarding methylases, E. faecalis isolates from swine livestock in China have shown a significant correlation between the presence of the gelE virulence gene (gelatinase protein) and erythromycin resistance (erm gene). The authors suggested that enterococci isolated from swine should be regarded cautiously because they may act as reservoirs for antimicrobial resistance and virulence genes (155).

Macrolide resistance and associated fitness costs have been reported in Campylobacter jejuni (156, 157), and the 23S rRNA mutation A2074C, which confers a high level of macrolide resistance, was associated with a fitness cost in this bacterium (156). Moreover, Zeitouni et al. reported in vitro experiments that demonstrated that macrolide resistance imposed a fitness cost; however, a spontaneous mutant that evolved in vivo had a colonization capacity that was similar to that of the susceptible strain (158). The effect of ribosomal mutations on antimicrobial resistance and fitness cost was described above (see “Resistance to Aminoglycosides and Effect on Virulence”).

Deletions in S. pneumoniae ribosomal protein L4 have also been related to resistance to macrolides, oxazolidinones, and chloramphenicol and to low fitness (159). Decreased growth rates may also be due to the fact that L4 mutations perturb the structure of 23S rRNA. Bacteria may develop compensatory mutations to adapt to a loss of fitness (160). This topic will be discussed in the Compensatory Mutations section below.

Resistance to Glycopeptides and Effect on Virulence S. aureus can become less susceptible to vancomycin in two different ways. One mechanism, which confers a moderate increase in MICs (resistance to vancomycin or glycopeptides, known as the vancomycin-intermediate S. aureus [VISA] or glycopeptide-intermediate S. aureus [GISA] phenotype, respectively), is mediated by chromosomal mutations that alter the cell wall physiology and result in increased cell wall thickness, which limits the access of glycopeptides to the d-Ala-d-Ala target in the peptidoglycan precursors (122). In another mechanism, S. aureus and Enterococcus spp. can develop full glycopeptide resistance by acquisition of van genes, which are responsible for the production of a modified peptidoglycan in which the precursors no longer contain the d-Ala-d-Ala dipeptide but contain a glycopeptide-resistant depsipeptide comprising d-Ala-d-Lac or d-Ala-d-Ser. VanA and VanB are the most prevalent types in Enterococcus clinical isolates, and VanA is most prevalent in the case of isolates of S. aureus.

The effects of these mechanisms on virulence are discussed below and summarized in Table 1.

Cell wall modifications.In an in vivo model of endocarditis (involving cardiac vegetations in mice), GISA isolates showed attenuated virulence, which was probably due to faster clearance from the blood and reduced fitness. Isolates with the GISA phenotype showed lowered infectivity, which could be explained by altered expression of global virulence regulators (130, 161, 162). Moreover, Peleg et al. found similar results in relation to the reduced susceptibility to vancomycin and the decreased pathogenicity of S. aureus in a nonmammalian model system (Galleria mellonella) (162).

In S. aureus, resistance to teicoplanin is associated with lowered fitness resulting from slower growth, thickening of the bacterial cell wall, increased N-acetylglucosamide incorporation, and decreased hemolysis (163). Transcriptomic studies showed downregulation of some virulence-associated genes as resistance increased. Elimination of the teicoplanin-resistant mutants and selection of teicoplanin-hypersusceptible survivors in the tissue cages indicated that glycopeptide resistance imposes a fitness burden on S. aureus and is selected against in vivo, with restoration of fitness leading to loss of resistance. Renzoni et al. found that teicoplanin-resistant methicillin-resistant S. aureus (MRSA) strains were more prevalent in intracellular locations, which might confer a significant fitness benefit over teicoplanin-susceptible MRSA strains and further protect them from cell wall-active antibiotics in which intracellular activity is limited (164).

Modified peptidoglycan target (d-Ala-d-Lac or d-Ala-d-Ser).A study of the variation in virulence of glycopeptide-resistant E. faecalis (VanA and VanB phenotypes) in a rat polymicrobial model of peritonitis suggests variations in virulence between E. faecalis that have the VanA and VanB gene cluster and those that do not. Slightly decreased bacterial proliferation and increased peritoneal and systemic inflammatory responses were observed for two transconjugant E. faecalis strains expressing VanA and VanB. The authors concluded that the increased fitness cost could lead to decreased concentrations of bacteria in the peritoneal fluid. However, the in vitro growth rate did not differ significantly between the strains, suggesting that the cost of resistance is not of major importance in these E. faecalis strains, especially strains containing the vanA gene (165).

Other studies show that induction of resistance to vancomycin greatly reduces the fitness of Enterococcus spp. For example, Foucault et al. showed that constitutive or induced resistance led to a great reduction in growth rate, colonization, and transmission of Enterococcus spp., which may explain the low occurrence of constitutively resistant clinical isolates. However, these authors also showed that both in vitro and in vivo, carriage of Tn1549 (encoding VanB-type vancomycin resistance), when inducible, had no cost to the Enterococcus host. These findings indicate that the regulation of resistance mediated by a two-component regulatory system drastically reduces the biological cost associated with vancomycin resistance (166). Moreover, the same authors reported that induction of S. aureus VanA-type resistance is costly for the MRSA host, whereas in the absence of induction, its biological cost is minimal (167). Thus, the potential for the dissemination of vancomycin-resistant S. aureus (VRSA) clinical isolates should not be underestimated.

Resistance to Oxazilidones (Linezolid) and Effect on VirulenceResistance or reduced susceptibility to oxazilidones remains very uncommon among staphylococci (especially S. aureus) and has mainly been reported to be associated with chromosomal mutations (rRNA mutations and rRNA methylation by the Cfr methyltransferase) brought about by prolonged exposure to this type of drug. Resistance to several antiribosomal agents, including oxazilidones, phenicols, lincosamides, and streptogramin A (PhLOPSA phenotype), is associated with the ribosomal modification brought about by the Cfr protein (168). Virulence studies of rRNA mutations, such as the rRNA methylation associated with resistance to oxazilidones (linezolid [LZD]), have been carried out (Table 1).

rRNA mutations.In S. aureus, the G2576T mutation in 23S rRNA genes, resulting in ribosomal target modification, caused resistance to linezolid (LZD) that was proportional to the number of mutated copies present in the bacterial genome (169). Mutational resistance usually occurs in coagulase-negative staphylococci (170). Other mutations associated with LZD resistance include A2059G and G2057A in enterococci and S. pneumoniae, respectively (122). Moreover, in S. pneumoniae, both the G2576T mutation in the 23S rRNA gene and mutations in spr0188 (50S ribosomal protein L3), spr01887 (ABC transporter ATP-binding/membrane-spanning protein), and spr0333 (conserved hypothetical/rRNA methyltransferase) conferred resistance to LZD. These compensatory mutations in both S. aureus and S. pneumoniae have been associated with changes in the fitness cost (Table 1). Hence, a combination of whole-genome transformation and sequencing was carried out to demonstrate the dual role of these mutations in both linezolid resistance and fitness compensation (171) (see Compensatory Mutations below).

rRNA methylation.The cfr gene was originally discovered in a multiresistant Staphylococcus isolate of animal origin (172). This gene encodes an RNA methyltransferase that modifies a conserved adenine at position 2503 of the 23S rRNA. This gene is typically plasmid borne in S. aureus isolates. cfr acquisition in S. aureus has been associated with low fitness cost. This could be the explanation for the apparent spread of the cfr gene among pathogens. However, in some clinical isolates of S. aureus, cfr coexpressed with the erm gene, which encodes a methyltransferase with another targeting 23S rRNA residue, A2058. The dimethylation of A2058 by Erm increases the fitness cost associated with Cfr-mediated methylation of A2503 (173, 174).

In S. pneumoniae, deletions in ribosomal protein L4 have been associated with resistance to oxazolidinones, macrolides, and chloramphenicol (see “Resistance to Macrolides and Effect on Virulence” above).

Resistance to Colistin, Polymyxin B, and Antimicrobial Peptides and Effect on Virulence

LPS modifications.Several mechanisms of resistance to polymyxins such as colistin and other antimicrobial peptides have been described, most of which are related to changes in lipopolysaccharides (LPS) and loss of affinity, mediated by two-component systems (TCSs), which will be discussed below and also in a separate section. Other mechanisms involved in antimicrobial peptide resistance include efflux systems and increased production of nonessential targets (Table 1).

The relationship between resistance to antimicrobial peptides (such as polymyxins) and virulence has been best characterized in Salmonella spp. Multiple genes are thought to be involved in LPS modification by addition of 4-aminoarabinose (Ara4N), which creates a positively charged LPS with low affinity and reduced binding to antimicrobial peptides. The ubiquitous two-component regulatory system PmrA-PmrB is one of the most important systems for increasing antimicrobial peptide resistance in response to environmental conditions. pmrA and pmrF operon mutants were unable to add Ara4N to lipid A but caused decreased virulence against the wild-type strains when orally administered, although not when they were intraperitoneally administered, in an in vivo mouse infection model. Thus, the addition of Ara4N is probably important to overcome the innate defenses of the host in intestinal tissues (175). Strains with reduced susceptibility to colistin showed mutations in pmrA and pmrB but also exhibited low fitness costs such as slightly slower growth in vitro; growth rates were unaffected in mouse infection (176). Other genes not regulated by PmrA-PmrB, such as surA, tolB, and gnd, which are necessary to develop polymyxin resistance, are also thought to be involved in virulence, as decreased virulence is observed in mice infected with strains with mutations of these genes (177).

This complex regulation system is able to activate genes involved in multiple bacterial functions and with different regulatory activities in each genus or species. For instance, in the phylogenetically close species Yersinia pseudotuberculosis, the PmrF operon is not PmrA-PmrB regulated as in Salmonella spp. but is regulated by another two-component system, the PhoP-PhoQ system. In Y. pseudotuberculosis, the PmrF operon is essential to develop polymyxin resistance but is not involved in virulence, unlike in Salmonella spp. (178). The PhoP-PhoQ operon is another important two-component system (179, 180) that can regulate membrane proteins, such as UgtL, YqjA, and PagP (181, 182), which are capable of modifying lipid A, thus inducing resistance to antimicrobial peptides, and which are involved in different ways in virulence in Salmonella spp. (180 – 185).

It is interesting to highlight the resistance to colistin observed in two extremely multidrug-resistant pathogens, A. baumannii and P. aeruginosa. Since the reintroduction of colistin for the treatment of infections caused by these agents over the past decade, colistin-resistant strains of A. baumannii have emerged both in vitro (186, 187) and in vivo during the course of clinical infections (188, 189). So far, two mechanisms of colistin resistance have been described in A. baumannii. The first involves total loss of LPS caused by a deficiency in lipid A biosynthesis, by inactivation of one of three genes involved, lpxA, lpxD, or lpxC (190, 191). In the second mechanism (studied by our research group), lipid A modification mediated by the addition of phosphoethanolamine results in loss of colistin affinity and subsequent resistance; these modifications are regulated by the PmrAB two-component system (186, 192). LPS and lipid A from A. baumannii are involved in diverse biological activities such as toxicity, pyrogenicity, mitogenicity, and activation of a proinflammatory immune response. It has been suggested that modification or loss of LPS production can increase resistance to colistin, while simultaneously decreasing bacterial fitness and virulence (193, 194). Although loss of infectivity has been observed in a strain with a high level of resistance to colistin, selected during treatment (194), it is not clear whether this is a universal phenomenon. Moreover, a colistin-resistant clone has been identified in Spain; this clone was selected during treatment with its infectivity intact, but it presented an altered antimicrobial resistance profile and became more susceptible to other antibiotics than the parental strain. Similar alterations in the MICs caused by LPS modification have been observed in other studies (190). Thus, there appears to be an inverse relationship between the increase in colistin resistance in A. baumannii mediated by changes in the LPS and the virulence of the species, or at least in the loss of resistance to other antibiotics, which can be considered a loss of fitness/virulence in an environment with high antibiotic pressure. In P. aeruginosa, the increased virulence is associated with increased resistance to polymyxin B and also to gentamicin and ciprofloxacin when the virulence is due to the development of swarming motility. This complex adaptation produces overexpression of different virulence factors, such as the type III secretion system, extracellular proteases, and factors associated with iron transport. The swarming cells of P. aeruginosa PAO1 exhibit greater resistance to those antibiotics, and although the molecular basis of this resistance has not been studied, it is probably influenced by the complex modifications necessary for this motility (195). Gooderham et al. have studied a P. aeruginosa psrA mutant, which exhibited supersusceptibility to polymyxin B and indocilin, owing to outer membrane permeabilization. This is thought to be a consequence of altered metabolism due to up- or downregulation of 178 genes in the psrA mutant, including dysregulated genes involved in virulence factors such as a type III secretion system, biofilm formation, and adhesion or motility (196). The TCS PhoP-PhoQ has also been shown to be involved in resistance and virulence in this species. The PhoQ sensor protein plays a major role in polymyxin B resistance, and it has also been demonstrated that mutation of phoQ caused reduced biofilm formation, attachment to epithelial cells, cytotoxicity, virulence in lettuce leaf, and competitiveness in rat lung infections (197).

Other antimicrobial peptide resistance mechanisms, which are possibly not PhoP-PhoQ or PmrA-PmrB regulated, have been described in Salmonella spp., such as the putative ABC transporter encoded by the yejABEF operon. Mutants with mutations of this transporter system (ΔyejF) showed increased susceptibility to polymyxin B and human defensins, as well as decreased proliferation capacity inside macrophages and epithelial cells. Decreased virulence was also observed in mouse gastric infection models (198).

Increased production of nonessential antimicrobial targets.Outer membrane vesicles (OMVs) are produced by most Gram-negative bacteria. They have been associated with resistance to antimicrobial peptides, such as colistin and polymyxin B; for example, an E. coli mutant that overproduces OMVs can survive treatments with these antibiotics due to the absorption capacity of the OMVs, probably because of the presence of surface constituents similar to that of the OM. Addition of OMVs to the culture medium increases the rate of survival against colistin or polymyxin B. Treatment with antimicrobial peptides induces vesicle production in the enterotoxigenic E. coli (ETEC) and K-12 E. coli ATCC strains, thereby altering their antibiotic resistance phenotype. Hypervesiculation may be an induced innate immune bacterial system of defense against antibiotics targeting the outer membrane (199). Overproduction of OMVs increases resistance to colistin and polymyxin and also increases the virulence of the strains, since OMVs can deliver a broad array of virulence factors to target human cells (see “Outer Membrane Vesicles” below).

Llobet et al. have recently demonstrated a new strategy of resistance in K. pneumoniae, S. pneumoniae, and P. aeruginosa (200, 201). Although the role of the bacterial capsule polysaccharide (CPS) is well known (200, 201), addition of CPS to nonencapsulated strains of these three species led to increased MICs of polymyxin B and the antimicrobial peptide human neutrophil alpha-defensin 1. Therefore, in addition to the role in virulence in avoiding phagocytosis and complement resistance, the CPS may represent a bacterial decoy for antimicrobial peptides, increasing both virulence and resistance in different pathogenic species (200).

HIGHLY VIRULENT AND MULTIRESISTANT WORLDWIDE DISSEMINATED CLONES

In recent years, clones that are resistant to many antibiotics and carry virulence factors have spread globally, and they are considered highly successful or high-risk clones (202, 203). These clones are derived from both animals (204) and humans (205). In this section, we highlight some of the most important of these clones, which are also included in Table 2.

View this table:
  • View inline
  • View popup
Table 2

Highly virulent and multiresistant worldwide disseminated clones

(i) Dissemination of the Enterococcus faecium epidemic-virulent clonal complex 17 (CC17), which is associated with the majority of hospital outbreaks and clinical infections of this species in five continents, is extremely widespread. This complex is characterized by ampicillin and quinolone resistance and by the presence of a putative pathogenicity island (206, 207). Some authors believe that E. faecium CC17 isolates have been circulating around the world for more than 30 years and that they have progressively acquired additional virulence and antibiotic resistance determinants, which would explain the recent success of this species in the hospital environment. An interesting study performed by Billström et al. aimed to determine the putative relationship between virulence and antibiotic resistance in E. faecium blood culture isolates over a 6-year period. Two hundred sixty-three isolates were screened, and the presence of Esp (enterococcal surface protein, which is involved in virulence) was significantly correlated with resistance to ampicillin, ciprofloxacin, and imipenem (P < 0.01) (208). Overall, the data suggest a positive correlation between resistance and virulence in Enterococcus spp. (at least in E. faecium), in contrast with that found in S. aureus and S. pneumoniae.

(ii) Streptococcus pneumoniae clone PMEN1 (Spain23FST81), which is estimated to have originated around 1970, is widely distributed throughout Europe, Asia, Africa, and the Americas. PMEN1 isolates are multilocus sequence type (MLST) 81, have a common pulsed-field gel electrophoresis (PFGE) profile, possess consistent multilocus enzyme electrophoresis (MEE) patterns, and have identical PBP patterns and ribotypes. In addition to penicillin, most PMEN1 isolates are also resistant to chloramphenicol and tetracycline, and many isolates also exhibit additional resistance to fluoroquinolones and macrolides (209). This clone has several virulence factors, even at the blp bacteriocin locus. This locus may also play a role in systemic virulence, as demonstrated in the mouse pneumonia model, in which a deletion of the blp locus response regulator leads to a decrease in systemic virulence relative to that of the wild-type strain (209). The regulatory portion of the locus consists of genes encoding a small peptide pheromone (blpC), a histidine kinase (blpH), and a response regulator (blpR), and it also encodes an ABC transporter (blpA-blpB), which cleaves and exports the pheromone, the bacteriocins, and their associated immunity proteins (210).

(iii) E. coli ST131 (O25:H4), associated with CTX-M extended-spectrum β-lactamases, has emerged internationally as a multidrug-resistant pathogen (211 – 213). This clone, which was described for the first time in 2000, became distributed worldwide by 2008 and is possibly the most widely distributed resistant clone (e.g., 30 to 60% of the fluoroquinolone-resistant isolates belong to this clone) (214, 215). Coselection of resistance genes (CTX-M) and virulence genes in plasmids of the IncFII group, such as pEK499 (Fig. 2B), appears to be important in explaining the extensive distribution (216) (see “Plasmids” below).

(iv) A multidrug-resistant P. aeruginosa strain with enhanced virulence, designated the “Liverpool epidemic strain” (LES), has recently been described in cystic fibrosis patients from the United Kingdom (97). This strain is characterized by upregulation of the efflux pump MexAB-OprM in relation to resistance to β-lactam antibiotics and aminoglycosides and by increased virulence in relation to the quorum-sensing system (see “Resistance to Antivirulence Components” below) (98, 99).

(v) The Clostridium difficile ribotype NAP1/027 epidemic hypervirulent and quinolone-resistant clone is genetically specific and displays high infectivity, which due to hyperproduction of toxins TcdA and TcdB, protease Cwp84, the high-molecular-weight S-layer protein, and fibronectin-binding protein Fbp68, combined with the antibiotic resistance, may have contributed to selection and worldwide spread of the clone, aided by residual concentrations of fluoroquinolones (217).

(vi) E. faecalis strains which are members of the clonal cluster with Bla (β-lactamase) and Vanr and which are isolated from endocarditis infections (E. faecalis that is β-lactamase positive and vancomycin resistant from endocarditis infections [BVE]) were found to contain a previously described putative pathogenicity island (PAI). Subtle variations within the structure of the pathogenicity island enable strains harboring the element to modulate virulence; these variations occur at a high frequency (218).

(vii) MRSA strain USA300 has been shown to be responsible for an epidemic of community-associated infections (219), involving mostly skin and soft tissue but also more serious invasive syndromes such as pneumonia, severe sepsis, and endocarditis. MRSA strains are particularly serious and potentially lethal pathogens that not only are resistant to several antibiotics but also possess virulence mechanisms, including toxins, adhesins, enzymes, and immunomodulators. An understanding of the biological basis of MRSA virulence and future directions for research, including potential vaccines and antivirulence therapies that are currently under development, might allow clinicians to treat and prevent MRSA infections more successfully. Moreover, Lin et al. have demonstrated the possibility of reverse zoonotic transmission of the MRSA isolates (220). These authors described the first case of a USA300 genotype in a pig. The presence of multiple virulence profiles within an MRSA genotype in these animals suggests the potential emergence of new MRSA clones by gain or loss of additional virulence genes.

(viii) P. aeruginosa clone ST175 has been characterized as a high-risk clone due to an increasing prevalence of nosocomial infections and multidrug resistance (203). It has recently been demonstrated that the extreme drug resistance is due to a combination of several mechanisms: AmpR-activating mutations in this clone (overexpression of AmpC), OprD inactivation, mutations in GyrA and ParC, MexXY-OprM overexpression, and the expression of the class 1 integron aadB gene. Indeed, AmpR can act as a global regulator, and its activation can be implicated in quorum sensing, alginate production, biofilm formation, and the expression of several other virulence factors (221).

COSELECTION OF MECHANISMS OF ANTIMICROBIAL RESISTANCE AND VIRULENCE

Horizontal gene transfer (HGT) is a very important mechanism (in addition to spontaneous mutation) responsible for the development of antibiotic resistance in bacteria. This is the process whereby DNA fragments, the so-called mobile genetic elements (MGEs), can be transferred between bacteria of the same or different species. The classification of MGEs involved in bacterial evolution and adaptation is continuously being updated. However, probably the most widely accepted classification is that of Burrus et al. (222), which considers that integrative and conjugative elements (ICEs) include transposons, integrons, integrative plasmids, genomic islands, and other, unclassified elements (i.e., those integrated in chromosomes). Plasmids and ICEs are the main genetic mechanisms for the dissemination and coselection of virulence and resistance genes, which are transferred and multiplied via three main ways of HGT: conjugation, transformation, and transduction. Indeed, biofilms appear to facilitate horizontal transmission due the high microbial density of the populations (222 – 224), and subinhibitory concentrations of antibiotics also appear to increase the rate of HGT (223).

PlasmidsPlasmids are extrachromosomal and self-replicating elements that are not essential to bacteria but which often carry and disseminate genes that confer to the bacteria certain characteristics such as resistance, virulence, the ability to metabolize rare substances, and persistence under extreme conditions. In particular, conjugative plasmids play an important role in the evolution of pathogenic bacteria because they are readily transmitted by horizontal transfer both between and within species (225, 226).

Some interesting studies have analyzed the nature of plasmids before the so-called antibiotic era. Studies of a collection of enterobacterial strains obtained between 1917 and 1954 have shown that most of the plasmids isolated nowadays are essentially the same as those isolated during the preantibiotic era. Analysis of 84 different plasmids, none of which carried a resistance determinant, revealed that 65 belong to current plasmid groups. Thus, the acquisition of antibiotic resistance through recruitment of new genes within the original plasmids, as a result of the use of the antibiotics, is of great clinical importance (227, 228).

The major incompatibility (Inc) group involved in transfer of resistance and virulence genes is the IncF group; transmission of IncF plasmids is a clear example of how virulence and resistance can increase via coselection, probably due to antibiotic pressure. This has led on numerous occasions to the emergence of strains or outbreaks of clones that are especially virulent and multidrug resistant. The wide dissemination of the E. coli sequence type ST131 clone is one example of this (see Highly Virulent and Multiresistant Worldwide Disseminated Clones above). Although there is no clear explanation for the successful dissemination, it appears that the IncFII group plasmids (e.g., pEK499) (Fig. 2B) often carry the CTX-M-15 β-lactamase (216) and may be involved in spread of the clone. These plasmids carry resistance genes in multiple families and also carry virulence genes (e.g., the pEK499 plasmid carries two copies of the vagC-vagD system, which is involved in cellular division and is necessary to maintain the virulence of K. pneumoniae). It is important to highlight the multiple maintenance systems present in these types of plasmids, for example, the Hok-Mok postsegregation killing proteins and the pemI-pemK and ccdA-ccdB toxin/antitoxin systems. These systems ensure stable transmission and maintenance in the absence of any antibiotic selective pressure (229, 230). Lavigne et al. have recently attempted to clarify the ample capacity of this clone to spread, as well as the involvement of the CTX-M β-lactamases. These authors developed two in vivo models to compare CTX-M-15-producing and non-ESBL-producing E. coli ST131 strains with non ST131 strains. They suggest that although expression of CTX-M-15 is not correlated with enhanced virulence, it can improve the persistence of a strain during infection. This indicates that the secret of the success of the clone is in achieving a perfect balance between virulence and antibiotic resistance (231). Although there is significant diversity in the structure of the plasmids and the evolution of resistance mechanisms that have affected clone ST131, plasmids that carry resistance genes have been essential in the rapid spread of these virulent clones of E. coli (232, 233).

Tetracycline resistance also can be coselected with virulence factors. For example, a virulence plasmid of a porcine enterotoxigenic E. coli (ETEC) strain carries a Tn10 transposon that carries the tetracycline resistance genes tetA and tetC (encoding efflux systems). The toxin-specific locus caused the enterotoxigenicity of the strain, which contains two heat-stable enterotoxin genes, sta and stb. In this example, the authors observed coselection of virulence and tetracycline resistance, but they did not analyze the biological cost of carrying this virulence plasmid (234). Coselection of tetracycline was also observed in C. perfringens in a study that analyzed the nonreplicating transposon Tn916, which is involved in the conjugation of a replicating plasmid carrying putative virulence genes and two tetracycline resistance mechanisms, tetA(P) (efflux system) and tetB(P), which provide ribosomal protection (235, 236).

Not only does antibiotic pressure promote the spread of plasmids with resistance determinants (and often also virulence factors), but certain environments (in which biodiversity is very high and there is a correspondingly large metagenome) encourage bacterial interchange and the distribution of these mechanisms. Plasmid pRSB107 (120 megabases), which was isolated from bacteria present in sludge from a sewage treatment plant, encoded resistance to at least 9 different antimicrobials in E. coli transformants. It also encoded or carried four putative virulence factors: an aerobactin iron acquisition siderophore system, a high-affinity Fe2+ uptake system, a glycerol-3-phosphate transport system, and the virulence-associated genes vagC and vagD (237). Under suitable conditions, plasmid chimeras can be created from different plasmids acquired by horizontal transmission from multiple environments (Fig. 2C).

Finally, another example of the recent evolution of coselection is the hybrid resistance-virulence plasmid of Salmonella spp. Some virulence plasmids which are very frequent in human infections, such as pSEV in S. enterica serovar Enteritidis or pLST and pSTV in S. enterica serovar Typhimurium, carry a conserved region of 7.8 kb carrying the spv genes (Salmonella plasmid virulence) and other virulence genes (238 – 242). It has been shown that 7 to 8% of ampicillin-resistant isolates of S. enterica serovar Typhimurium in the United Kingdom and Spain carry the pUO-StVR2 virulence-resistance hybrid plasmid, which is derived from the plasmid pSTV after acquisition of a 45-kb region including the class 1 integron InH, with genes encoding resistance to at least five different antimicrobial families (243, 244).

The TraT protein, which is an external outer membrane lipoprotein associated with plasmid conjugation and also with several virulence mechanisms (e.g., serum resistance, phagocytosis, and biofilm formation), also plays an important role. Thus, plasmids have a doubly important role, as they spread resistance genes and the traT genes are directly involved in bacterial virulence (3, 245).

Carrying plasmids that encode both resistance and virulence factors leads to selection of resistance determinants in bacteria in noninfective environments subjected to antibiotic pressure. Reciprocally, in infective environments, simultaneous selection of virulence determinants and resistance factors can occur in bacteria, even in the absence of antibiotic selective pressure (3). Thus, coselection appears to have occurred in the recent evolution that has taken place in the postantibiotic era, and it could help bacteria to adapt more easily to new environments. The distribution of these types of plasmids among common human pathogens may become a major health problem in the near future.

Integrative and Conjugative ElementsIntegrative and conjugative elements (ICEs) are self-transmissible mobile genetic elements that help in the horizontal dispersal of genes located in another higher DNA molecule with replicative capacity, such as plasmids and chromosomes. With the introduction of new methodologies, such as metagenomics and massively parallel sequencing, it has been shown that ICEs may have an even more significant impact than plasmids in HGT (246). Hypothetically, genetic elements such as integrons and transposons can capture virulence genes and disperse them jointly with resistance genes, although not much is known about the relationship between virulence and resistance factors in the same ICE, except for some specific examples such as those described below. This may suggest the difficulty of coselection of both types of factors by ICEs. However, there may be some bias, since many studies seek the cause of the dissemination of antibiotic resistance in bacterial populations by exclusively locating and sequencing the resistance markers and the neighboring genetic locations. Furthermore, transposons and integrons that carry virulence genes are less extended than those carrying resistance genes or catabolic pathways; indeed, virulence factors are usually related to prophage-like structures (which are less likely to carry resistance genes). The main explanation for this is the difference in the evolutionary time scale of virulence and resistance for the hosts and the drugs, respectively. The current pathogens are the product of a long period of evolution along with the host and a short but intense period of evolution, of only a few decades, involving antibiotic pressure. While phages have a narrow host range, transposons can readily insert themselves into a broad host range of plasmids, thus providing functions to a large number of hosts (247); this facilitates the spread, in this case, of antibiotic resistance factors.

However, there are some clear examples in which coselection of resistance and virulence occurs via ICEs. In Vibrio cholerae, the enzyme bis-(3′,5′)-cyclic dimeric GMP increases biofilm formation and decreases virulence and motility, so that it is considered an important factor for persistence in the environment, and is regulated by diguanylate cyclases (DGCs). Two DGCs, DgcK and DgcL, are encoded by integrating conjugative elements of the SXT/R391 family, and thus the acquisition of these ICEs could improve the survival of this species in aquatic environments. SXT/R391 ICEs are directly involved in the transmission of multiple drug resistance in different species, including Vibrio species (248). Indeed, analysis of some isolates from cholera outbreaks has revealed the involvement of SXT/R391-like genes in the transmission of virulence and resistance (248, 249). The in vitro plasticity and capacity of the SXT-related ICE from Vibrio cholerae to transfer virulence genes to other species such as E. coli has also been demonstrated (250).

Genomic islands are also involved in the dissemination of virulent and resistant isolates; for instance, Salmonella genomic island 1 (SGI1) encodes resistance to different antibiotics. The S. enterica serovar Typhimurium phage type DT104, carrying SGI1, is disseminated worldwide, like other major clones. Because of its virulence and resistance gene repertoires, isolates with an SGI1 variant are a risk for rapid dissemination (141, 251, 252). The OmpR-EnvZ operon system, which is encoded in Salmonella pathogenicity island 2, is also involved in the regulation of resistance and virulence. This system responds to environmental conditions by modifying the expression of OmpC and OmpF porins, which are involved in antibiotic resistance in this species. Furthermore, the OmpR-EnvZ system also regulates another system encoded in the same pathogenicity island, the SsrA-SsrB operon, which in turn regulates the type III secretion system. OmpR mutants are unable to replicate inside the macrophage cell, thereby reducing its virulence in the absence of this operon (253, 254). In another example, the entire genome of Streptococcus suis, a zoonotic agent of disease in young pigs which can also cause infection in humans, has been sequenced. The major finding was a pathogenic island of 89 kb, named ICESsu SC84, which is a composite structure with several integrated MGEs. This island encodes several resistance mechanisms, such as resistance to aminoglycosides and tetracyclines and an antibiotic export/resistance system; it also encodes a surface-anchored protein, LPXTG, a virulence factor that facilitates binding of bacteria to the eukaryotic cell and is also located in Streptococcus agalactiae (255, 256). Sequencing of strain ATCC 17978 of A. baumannii revealed the existence of up to 28 putative alien islands (islands formed by genes obtained from other species), including 17% of the total open reading frames (ORFs). This indicates that this species has acquired a large amount of foreign DNA and also highlights the genetic plasticity of the species. Sixteen of these islands contain putative genes involved in virulence, such as type IV secretion systems and others. Seven different putative alien islands also contained genes that probably encode drug resistance proteins (on the basis of their sequences). Although no island that encoded virulence and resistance factors together was identified, this study highlights the genetic plasticity of A. baumannii (as it can capture foreign genes of both types easily), which appears to be one of the secrets of its successful dissemination and persistence in recent decades (257, 258).

Biofilms play an important role in HGT. The structure of biofilms promotes HGT, especially by conjugation, and because of the high density and close proximity of the cells, the conjugation itself can even stimulate biofilm production. Indeed, transformation appears to be necessary for biofilm formation and stabilization (259). A type IV secretion system is involved in biofilm formation and contributes to cell-to-cell contact, thus mediating DNA transfer (260). There is therefore a positive feedback between the horizontal exchange of genes and biofilm formation, which favors movement of resistance genes and virulence factors, especially in the presence of antibiotic selective pressure (261, 262).

Phage-Mediated TransductionIn transduction, fragments of bacterial DNA are included as part of viral DNA, and when this viral particle infects other bacterial cells, DNA is integrated and replicated in the host bacterial cell. There are numerous examples of different virulence genes carried by prophages in E. coli: e.g., Shiga toxin (STX) (263, 264); genes of effector proteins such as bacteriophages, nleA-H, and Cif; and cytolethal distending toxin (CDT) (265). These prophages can spread virulence factors to other species that may already possess resistance mechanisms that favor the persistence or dissemination of both in the environment. Recently, a particularly virulent outbreak comprising 3,842 cases of human infections was produced in Germany by a Shiga toxin-producing E. coli (STEC) strain belonging to serotype O104:H4 with virulence features common to the enteroaggregative E. coli pathotype, which previously carried the plasmid-encoded TEM-1 and CTX-M-15 β-lactamases. The Shiga toxin was probably transduced from other enterohemorrhagic E. coli strains (266, 267). Indeed, the presence in animal environments of bacteriophages carrying different resistance genes, such as bla TEM, bla CTX-M, and mecA, has recently been demonstrated, suggesting their capacity to act as environmental vectors of virulence and resistance (268).

Finally, we will comment on the role of the SOS response (bacterial response to the DNA damage) in the activation of production of lysogenic prophages and, therefore, the increased genetic exchange by transduction. For example in S. aureus, SOS response-inducting antibiotics, such as β-lactams and ciprofloxacin, may favor the dissemination of virulence factors by promoting replication and horizontal transfer of pathogenicity islands (130, 161).

Outer Membrane VesiclesMembrane vesicles, which are released from the cell envelope, are a vehicle for numerous lipids and proteins and play an important role in the interaction between host and pathogen. The vesicles are a relatively novel or poorly studied mechanism of coselection and joint dissemination of virulence and resistance factors. It has been demonstrated that OMV production increases in response to bacterial stress or environmental factors, e.g., during the colonization or infection of host tissues (269, 270).

Indeed, OMVs often contain numerous virulence factors, including adhesins, toxins, antigens such as lipopolysaccharide (LPS) (271), and other outer membrane (OM) components that influence the infection and host response. Thus, enterotoxigenic E. coli secretes the enterotoxin LT, which is delivered by the OMVs from the OM into mammalian cells (272). Staphylococcus aureus releases membrane vesicles (not OMVs), produced during in vivo infection in a mouse pneumonia model, harboring class A β-lactamase and virulence-related proteins, which are able to induce apoptosis of HEp-2 cells (273). In the presence of gentamicin, P. aeruginosa increases the release of membrane vesicles carrying hydrolytic enzymes (274). Quorum-sensing molecules or adhesins are also transported by OMVs and enable the bacteria to interact with eukaryotic cells (275).

However, it is not only virulence factors that can be directly transported on vesicles. Horizontal transfer of plasmids carrying antibiotic resistance genes has been demonstrated to occur through OMVs, which reveals a direct link between resistance and virulence. Our group has demonstrated that A. baumannii releases Omp33-36 and OmpA porins (involved in resistance and virulence) within OMVs (276). Also in A. baumannii, we have studied an MDR epidemic strain, AbH12O-A2, that is able to release AmpC and OXA-24 β-lactamases (277). This type of mechanism of spread of virulence and/or resistance determinants probably occurs in most pathogenic species.

In general, bacteria produce a relatively enriched protein profile of virulence factors within OMVs compared with the virulence factor complement of the OM (271). Therefore, more studies with pathogenic species are required to determine the real importance of vesicles as vehicles of codissemination of virulence and resistance factors.

COMPENSATORY MUTATIONS

In the recent past it was assumed that the development of antibiotic resistance was inexorably linked to virulence and to fitness costs and that in the absence of antimicrobials in the environment, the susceptible strain would be more competitive than the resistant strain (which may display, e.g., lower growth rates, invasiveness, and transmission capacity). However, antimicrobial treatment could hypothetically reduce the fitness of the susceptible strain, thus creating more favorable circumstances for resistant mutants with a higher fitness in this environment and leading to the development of resistant populations. Many studies in recent years have highlighted the importance of the ability of resistant mutants to adapt and recover their fitness and virulence by secondary-site mutations or compensatory mutations. Molecular studies with different bacteria (both laboratory and clinical strains) show that the recognition of additional compensatory mutations is key to understanding the evolution of microorganisms in recent decades, during which antimicrobial agents have been extensively used. However, the type and number of compensatory mutations and the level of compensation depend on multiple factors, such as the particular species, the resistance mechanism, and the environmental conditions. A recently published review by Andersson and Hughes (278) highlights some of the main examples of chromosomal compensation of fitness costs. There are three ways of restoring the fitness of resistant mutants: direct restoration of the efficiency, replacement of the function by another similar function, and reduction of the need for that function, as explained in further detail below:

(i) Some recent studies provide a better understanding of fitness compensation. For example, Billal et al. carried out an interesting whole-genome analysis with transformants of S. pneumoniae that were susceptible or resistant to linezolid (171). On the basis of the transformation of the genome of a resistant mutant into two susceptible strains, the group characterized all mutations associated with resistance to this antibiotic and mutations associated with adaptive compensation. The involvement of some of the genes in resistance and fitness compensation investigated in this study is shown in Fig. 5A. The cumulative effect of two different ABC transporters (encoded by spr1021 and spr1887) may at least partly increase the fitness cost of chromosomal mutations involved in linezolid resistance (23S rRNA mutations). Excessive intracellular concentrations of linezolid due to modification of the target (23S rRNA) may be compensated for by the overexpression of ABC transporters, especially Spr1887, which is responsible for the extracellular excretion of free linezolid. Other mutations, such as amino acid changes in the 50S ribosomal proteins L3 and L16, are involved in restoring the loss of fitness in these linezolid-resistant strains of S. pneumoniae. These changes are probably involved in enhancing the stabilization of the peptidyltransferase center of the ribosome (involved in the translation of proteins), modified with the unfavorable G2576T 23S rRNA mutation (171). Thus, in this case, two different types of events have compensated for the loss of fitness: increased expression or overexpression of a new function (ABC transporter) and direct restoration of the efficiency of an affected function (modification of L3 and L16 ribosomal proteins). A similar example is shown in Fig. 5B. Björkman et al. performed several studies with a mouse infection model (278 – 280) and showed that in mutant strains of S. enterica, the increased fitness cost of high-level resistance to streptomycin could be compensated for by single mutations in the rpsL gene. This gene encodes 30S ribosomal protein S12, which offers streptomycin resistance at no cost (K42R) or with a fitness cost (K42N). However, if in addition to the K42N mutation, the strain suffers new compensatory mutations in the rpsD gene (which encodes 30S ribosomal protein S4), such as K205T, the fitness cost will be compensated for (278 – 280).

Fig 5
  • Open in new tab
  • Download powerpoint
Fig 5

(A) Relationship between resistance, fitness, and compensatory mutations. The figure reflects the fitness (measured as growth capacity) of the S. pneumoniae wild-type (WT) strain (1974), the linezolid-resistant mutant (1974M1), the T-7 mutant (the 1974 WT strain with the main mutation involved in resistance, the 23S rRNA mutation G2576), which is less fit than strain 1974M1 (indicating the existence of compensatory mutations in the latter), the T-7spr1021 mutant (T-7 mutant with overexpression of the spr1021 gene, encoding an ABC transporter), which displays increased resistance to linezolid but with a clear biological cost, and finally the T-7spr0333,spr1021,spr1887 mutant (T-7 mutant with overexpression of the spr1021 and spr1887 genes and also the methyltransferase gene spr0333), which appears to restore the original fitness by the action of the new ABC transporter encoded by spr1887 (those commented on in the text are highlighted). (Reprinted from reference 171, which was published under an open-access license.) (B) High-level resistance to streptomycin in mutants of S. enterica subsp. enterica serovar Typhimurium. The fitness costs are reflected on the y axis. The K42R mutation in the protein encoded by rpsL gene is free of any fitness cost; however, the appearance of the K42N mutation in the same protein is associated with a biological cost, which can be almost totally compensated for by the secondary mutation K205T in RpsD protein. (Modified from reference 278 by permission from Macmillan Publishers Ltd.)

(ii) Another way of restoring fitness is to replace one function with another function of similar efficacy. This strategy is used by strains of S. enterica that are resistant to peptide deformylase inhibitors (PDFIs), such as actinonin. In most bacteria, translation starts with a formylated Met-tRNAi, and when translation is complete, the formyl group is removed by the peptide deformylase enzyme. The PDFIs inhibit peptide formylase activity by accumulating intracellular toxic formylated peptides. Therefore, to acquire resistance to PDFIs, S. enterica can gain mutations in the fmt and folD genes, thereby decreasing the addition of formyl groups to the Met-tRNAi; the translation and growth rates become reduced because of the need to initiate translation with unformylated Met-tRNAi. In this case, fitness is restored by amplification of tandemly repeated metZ and metW genes that encode tRNAi. Increased expression of these genes results in increased tRNAi levels, which can compensate for the lack of addition of formyl groups to the Met-tRNAi and allow initiation of translation without formylated Met-tRNAi. In Salmonella, peptide deformylase activity is replaced by high tRNAi levels, so that resistance to PDFIs is acquired at the lowest possible cost (281).

(iii) The third way to restore the fitness by means of compensatory mutations is to reduce the need of the bacteria for the altered function. Albarracín et al. (282) have studied an example of this in β-lactam-resistant transformants of S. pneumoniae induced by mutations in three penicillin-binding proteins, PBP1a, PBP2x, and PBP2b. Basically, the simple PBP2b mutant used in this study had resistance to piperacillin but also reduced fitness relative to that of the parental strain (measured in both in vitro and in vivo models). Thereafter, transformation with two new PBP mutations, in PBP1a and PBP2x, maintained the piperacillin MIC and increased the cefotaxime MIC; remarkably, the transformation also increased the fitness of the triple transformant of S. pneumoniae. In this example, the proteins PBP1a and PBP2x not only showed a complementary function of PBP2b (cell wall maintenance) but also contributed to increasing the resistance to β-lactams antibiotics (282).

These and other recent studies (278, 283 – 288) highlight the importance of compensatory mutations that enable bacteria to adapt to and subsist with the biological cost associated with the gain in antibiotic resistance. Handel et al. developed a mathematical model that helps us to understand how far the adaptive phenomenon is relevant in the process of emergence of resistance (5). One of the most important aspects regarding the possible emergence of resistance as a result of compensatory mutations is the level of treatment to which a specific microbial population is exposed. A diagram summarizing the dynamics of the development of resistance, proposed by these authors, is shown in Fig. 6. This theoretical model shows that once a resistant mutant that is less fit than the parental strain appears in an environment, it could eventually restore its fitness and could compete with the original susceptible strain if it is able to survive long enough to acquire one or more advantageous compensatory mutations. This model considers four possibilities. In a hypothetical first situation, A, without treatment, resistant mutants can appear only via unlikely mutations, which also have a fitness cost and therefore will not prevail; resistance will not emerge. Oceans or seas are examples of such environments in which antibiotics are present at low levels. Similarly, in hypothetical situation B, if the treatment covers only a small percentage of the population or antimicrobials are present at low levels, resistant mutants are unlikely to appear, but they may appear, because of the low number of individuals subjected to antibiotic pressure. In this scenario, resistant mutants could acquire a level of fitness similar to that of the parental strain. This could include bacteria that colonize or infect anatomical niches with low levels of distribution of the antibiotic in a treated host (e.g., gut microbiota in treatment for otitis). In a third situation, C, in which treatment levels are higher, resistant mutants with a low degree of fitness would probably emerge; these could lead to the emergence of resistant mutants with restored fitness due to compensatory mutations, although this is unlikely due to the low number of resistant mutants. A real example of this is the nosocomial environment, in which antibiotics are present and there is a high risk of selection of resistant clones. In the last case, D, in which the population would be massively subjected to the drug, emergence of resistant mutants from the original generations or from the following generations would be likely; these mutants would have restored fitness and would therefore be able to prevail over time, for instance, in treatment of infection of an animal or human host with antimicrobial therapy (5).

Fig 6
  • Open in new tab
  • Download powerpoint
Fig 6

Theoretical model proposed by Handel et al. of the emergence and persistence of antimicrobial resistance in different ecological niches. The bars indicate the fitness of the strains in a given situation, the solid arrows indicate acquisition of mutations that occur frequently due to the large size of the original population, and the dashed arrows indicate acquisition of mutations that occur infrequently in a small part of the original population. If the resistant mutant is less fit than the wild-type strain, it will tend to extinction by competition; however, if during competition the resistant strain develops compensatory mutations, it could eventually emerge and persist. The antibiotic levels in the environment will largely determine this selection. (A) In an environment without antibiotic treatment (e.g., seas), resistant strains are associated with low fitness and will not emerge. (B) In an environment with a certain level of antibiotics (e.g., during infection in a compartment of the treated patient with a low level of antibiotics or without antibiotic distribution), the fitness of the wild-type strain is reduced, which enables emergence of a resistant mutant. One frequent conversion and two infrequent conversions are required. (C) In an environment with antibiotics (e.g., a nosocomial environment), resistant mutants readily emerge, and only one infrequent conversion is necessary. (D) In an environment with a massive presence of antibiotics (e.g., during antibiotic treatment), the low fitness of the original population readily enables the emergence and persistence of resistant populations. (Reprinted from reference 5, which was published under an open-access license.)

Another theoretical model of the emergence of resistant mutants on a time scale that includes the proportion of treated individuals is shown in Fig. 7A. This illustrates several resistant mutants for which the fitness costs are different from those associated with the susceptible strain. The large number of treated individuals would also increase the possibility of emergence of resistant mutants in a short time. Similarly, the probability of emergence increases according to the fitness and the percentage of treated individuals, as shown in Fig. 7B. It is important to highlight the nonlinear dependence between the time/probability of appearance of resistant prevalent mutants and the percentage of the population treated. As reflected in the figure, the temporal changes or the probability of emergence is much higher when low levels of the population are treated, although these changes are more unlikely to occur with high levels of treatment. This should be considered when implementing treatment strategies and when analyzing epidemiological data.

Fig 7
  • Open in new tab
  • Download powerpoint
Fig 7

(A) Time until emergence of resistance, based on a theoretical model obtained from simulations of the deterministic model of years until emergence of the resistant strains (see reference 5 for more details). Fitness levels of the resistant strains 1, 2, and 3 are 75%, 85%, and 95%, respectively, of those of the susceptible strain in the absence of antibiotics. Vertical lines represent the level of treatment necessary for the fitness of the resistant strains to equal that of the susceptible original strain. The conversion rate of the strains due to the compensatory mutations equals 10−1 (for other rates, see reference 5). (B) Probability that resistance will emerge within 1 year, based on a theoretical model obtained from stochastic simulations. The parameters used are the same as for panel A. (Reprinted from reference 5, which was published under an open-access license.)

These types of models help us to understand why compensatory mutations are fundamental to the wide dissemination of resistant clones, despite the initial increase in fitness costs and virulence. The role of such advantageous mutations in the persistence or reversion of the resistant mutations is not entirely clear. Theoretical findings supported by clinical and experimental studies suggest that resistance and compensatory mutations are easier to achieve than reversion mutations, and therefore compensatory mutations are a barrier to the loss of resistance in resistant adapted mutants (289, 290). However, the genetic reversion of resistant mutants after a period of absence of drugs has been described in both experimental and clinical studies, even in individual patients (289). According to the model of Schulz zur Wiesch et al., these situations, in which decreased resistance occurs, may be explained by clonal changes in the environment, even when the resistant clones are as fit as the susceptible strains (289 – 291), and the reversal of resistance through genetic events is less likely (289, 291). At the same time, reversal will be possible when the compensatory mutations are not sufficient to balance the fitness of the original strain. Often as a consequence of a decrease in antibiotic pressure, the resistance levels of a bacterial population decrease to minimal levels but do not disappear, thus making the persistent population more resistant than the original population, even in the absence of direct pressure (288, 292). In addition to searching for explanations for the persistence of resistant bacterial populations in the absence of antibiotic pressure, the increasingly common phenomenon of coresistance should be taken into consideration.

GLOBAL RESPONSES AND THEIR EFFECT ON ANTIMICROBIAL RESISTANCE AND VIRULENCE

Due to the extent of the review, we do not discuss in this work the interplay between antimicrobial resistance and virulence on overall and global stress responses depending on MarA, SoxS, and RobA (among some other examples), as this subject warrants a separate review.

Two-Component Regulatory SystemsBacterial pathogens can survive hostile environmental conditions during host infection by modulating their genetic arsenal. They often use two-component systems (TCSs) to regulate their responses and adapt to environmental changes. Such systems are frequently involved in changes in antibiotic resistance and virulence, as previously mentioned. These systems comprise a histidine kinase sensor protein, which is integrated in the inner membrane, and a cytoplasmic response regulator. The function of both proteins is mediated by phosphorylation reactions and conformational changes (293 – 296).

P. aeruginosa strain PAO1 carries up to 10% of its genes as regulatory genes, including those encoding 72 response regulators and 62 sensor kinases. Of these gene products, several TCSs are involved in both virulence and antibiotic resistance: PhoP-PhoQ (297), PmrA-PmrB (298), CbrA-CbrB (11), WalK-WalR (299), Ppr-PprA (300), GacA-GacS (301), and PvrR (302). Similar TCSs have been studied in Salmonella (PmrA-PmrB and PhoP-PhoQ) (180, 303, 304) and E. coli (BasR-BasS and PmrA-PmrB) (304, 305).

PhoP-PhoQ.The TCS PhoP-PhoQ governs virulence, motility, invasion, intracellular survival, the adaptive response to low environmental concentrations of Mg2+, resistance to aminoglycosides and antimicrobial peptides, and multiple cellular activities in several Gram-negative species (179, 295). Groisman proposed a model that reflects the role of PhoP-PhoQ in Salmonella and how it interacts with PmrA-PmrB (180) (Fig. 8). Low concentrations of Mg2+ promote transcription of PhoP-activated genes, and high concentrations of Mg2+ promote repression of these genes. Addition of Mg2+ to Salmonella culture medium increases the susceptibility of the bacteria to magainin (an antimicrobial peptide) by more than 1,000 times (306). Approximately 40 genes are regulated by the PhoP-PhoQ system in Salmonella (307), including virulence genes such as mgtCB, which is involved in intramacrophage survival (308), and possibly the spv and ssa/sse genes, isolated from a virulence plasmid and a pathogenicity island, respectively (309, 310). In Salmonella, mutations of the PhoQ sensor alter the Mg2+ sensitivity threshold and render the bacteria avirulent (306). However, PhoP-PhoQ also mediates resistance to antimicrobial peptides or polymyxin B through activation of pagL and pagP, encoding a lipid A 3-O-deacylase and a lipid A palmitoyltransferase, respectively. These modifications decrease the negative charge of the LPS, thus affecting the electrostatic interactions and decreasing the affinity between the LPS and colistin or polymyxin B (311, 312).

Fig 8
  • Open in new tab
  • Download powerpoint
Fig 8

Model describing the signals controlling expression of PhoP-PhoQ-regulated determinants and the interaction between the PhoP-PhoQ and PmrA-PmrB two-component systems, as well as some of the genes and phenotypes governed by the PhoP-PhoQ system. (Reprinted from reference 180 with permission.)

Similarly, in P. aeruginosa, PhoP-PhoQ regulates resistance to polymyxin at low concentrations of Mg2+. Overexpression of this system is associated with a high degree of resistance to polymyxin B (313), and a phoP laboratory mutant was found to be highly susceptible to this antibiotic (314). A phoQ mutant also exhibited high susceptibility to quinolones (315). On the other hand, the PhoQ sensor is necessary in P. aeruginosa for biofilm formation (316), and different in vivo studies with phoP mutants have demonstrated the role of this TCS in virulence in a neutropenic mouse model (313) and in chronic rat lung infection (295), as well as reduced twitching motility, biofilm formation, and cytotoxicity to human lung epithelial cells and loss of competitiveness in chronic rat lung infections (197). PhoP orthologs associated with antimicrobial peptide resistance and virulence have been found in other species, such as E. coli, S. flexneri, Y. pestis, and M. tuberculosis (317 – 320).

PmrA-PmrB.The TCS PmrA-PmrB (also known as BasR-BasS), which can also be induced by PhoP, regulates other LPS modifications. However, PmrA-PmrB regulation can be PhoP-PhoQ independent and can be activated by high concentrations of Fe3+ or low pH (Fig. 8). One of the main roles of this system is the modification of lipid A by the addition of 4-aminoarabinose and phosphoethanolamine, which decreases the negative charge of LPS (321, 322). Addition of 4-aminoarabinose and phosphoethanolamine is mediated by the pmrE gene or the operons pmrHFIJKLM (323) and pmrC (324), respectively. Strains of Salmonella with mutations in these genes exhibit decreased virulence in vivo, which highlights the role of these mechanisms in virulence (175). Interestingly, the antimicrobial resistance mediated by 4-aminoarabinose is associated with higher survival in murine intestine, which may be related to the fact that LPS is essential for recognition of the host immune system; modifications to the LPS may alter the identification of the microbial pathogen and avoid the innate response with a decreased Toll-like receptor–LPS interaction. This would also be associated with antimicrobial peptides and polymyxin resistance (321). In E. coli, treatment with bile salts leads to induction of PmrA-PmrB, lipid A changes, and upregulation of the efflux system AcrAB, which is involved in resistance to multiple antibiotics (305).

The PmrA-PmrB system, which has also been described in P. aeruginosa, induces modification of lipid A, by the addition of 4-aminoarabinose, and subsequent antimicrobial peptide resistance (295). Modifications to the LPS which are induced by PhoP-PhoQ, PmrA-PmrB, or other systems involving palmitate and aminoarabinose are very similar to those produced by this species in cystic fibrosis, in which the host inflammatory response is increased (314).

CbrA-CbrB.The TCS CbrA-CbrB of P. aeruginosa, previously described as being involved in the carbon and nitrogen metabolic usage, is also involved in several mechanisms of antibiotic resistance (to polymyxin B, ciprofloxacin, and tobramycin) and virulence (swarming, biofilm formation, and cytotoxicity). A recent study with a cbrA deletion mutant of P. aeruginosa showed enhanced biofilm formation and in vitro cytotoxicity in human bronchial epithelial cells but also showed defective swarming motility (which is involved in a complex process of adaptation, involving different virulence genes). Indeed, this system can regulate the expression of PmrA-PmrB and PhoP-PhoQ in P. aeruginosa (11).

WalK-WalR.Although the WalK-WalR system in S. aureus is known to be involved in the control of cell wall synthesis, single amino acid mutations in both genes of vancomycin-susceptible S. aureus (VSSA) strains have recently been shown to cause resistance to vancomycin and daptomycin. In addition, the virulence decreased dramatically in an in vivo model (G. mellonella) of S. aureus infection, and the in vitro biofilm formation also decreased. These mutations partly reproduced the typical VISA phenotypes (299).

Other TCSs involved in virulence and resistance have been described, such as RocS2/RocS1-RocA1 of P. aeruginosa, which is able to control the cupC gene (involved in assembly of fimbriae) and the mexAB-oprM genes (encoding a multidrug efflux pump) (325). Other examples, also in P. aeruginosa, include the PprA-PprB system, which is involved in aminoglycoside resistance, outer membrane permeability, cytotoxicity mediated by the type III secretion system, biofilm formation, and quorum sensing (300, 326, 327), and the GacS-GacA system, which is associated with the production of small-colony variants that affect motility, biofilm formation, and antibiotic resistance (301). The RppA response regulator of Proteus mirabilis is necessary for the natural resistance of this species to polymyxin B and is also involved in biofilm formation and urothelial cell invasion (328).

These and other studies note the important role of TCSs in the development of in vivo resistance to different families of antibiotics, as well as the regulation of several bacterial processes, including virulence. Inactivation by mutations in these systems often involves loss of virulence.

Stress by DNA Damage: SOS ResponseBacterial pathogens are subjected to many external assaults that can damage the DNA; the SOS response is the main mechanism for repairing damaged DNA. The SOS response involves several proteins but only two mayor enzymes: LexA, which regulates the repair system inhibiting gene expression through obstructing the binding of RNA polymerase to DNA (329), and RecA, which interacts with the single-stranded fragments of DNA (damaged DNA) and involves autocatalytic cleavage of LexA and other repressors, finally producing expression of the SOS response genes (330, 331). Once the damaged DNA is repaired, RecA expression decreases and LexA represses expression of all the SOS response genes. Although this repair mechanism is widespread among bacteria, it can vary greatly between species (332).

The SOS response is induced by antibiotics; e.g., some quinolones cause direct DNA damage (333), some β-lactams do not directly damage DNA but interfere with cell wall synthesis (334), and some quinolones interfere with DNA replication, even at subinhibitory levels (335). This response is also involved in the following: transmission of virulence factors such as Shiga-like toxin in E. coli (336), dissemination of mobile elements such as pathogenicity islands in S. aureus (130, 161) and E. coli (337), and increased expression of genes necessary to transfer the integrating conjugative element SXT of Vibrio cholerae, a carrier of mechanisms of resistance to multiple classes of antibiotics (338). An interesting finding by Guerin et al. (339) involved a conserved LexA-binding motif overlapping the promoter regions of chromosomal and mobile integrons (often carriers of multiple antibiotic resistance genes). Thus, in a normal environment, the SOS system represses the integrase protein, but under stressful conditions, the SOS response may activate the reordering of the integrons in the chromosome and facilitate the acquisition of exogenous resistance cassettes. Thus, exposure to antibiotics may induce the SOS response and activate integron recombination. This mechanism would not usually have any biological cost, under usual conditions, because it would not be activated. All these findings indicate that the SOS system is not only a DNA repair mechanism but also an important mechanism of induction and dissemination of antibiotic resistance mechanisms and virulence factors.

A clear example of the above is the study by Bisognano et al. of S. aureus strains that are resistant to quinolones (131). Exposure of these strains to low concentrations of ciprofloxacin raises the fibronectin-mediated attachment, which enhances the virulence by tissue attachment and cellular invasion. Electrophoretic mobility assays showed specific binding of the repressor LexA to recA and also to fnbB, which encodes a fibronectin-binding protein, a known virulence factor in S. aureus. Thus, exposure to subinhibitory concentrations of ciprofloxacin may enhance production of a virulence factor involved in colonization and invasion, which could favor the carrier state and increase the risk of acquiring a severe infection.

It has been shown in E. coli that β-lactams, fluoroquinolones, and trimethoprim induce the SOS response, thereby decreasing the bactericidal activity of these antibiotics (334, 340, 341). Similar induction of the SOS response has also been described in V. cholerae (342) and S. aureus (130, 161). Indeed, the SOS response by itself can also induce the expression of virulence factors (130, 161, 343). Mellies et al. observed, in enteropathogenic E. coli (EPEC), that the virulence factor type III secretion system, encoded by the locus of enterocyte effacement (LEE), showed LexA-dependent regulation (343). EPEC produces intestinal lesions, mediated by a type III secretion system, and protein effector molecules, which are injected into the host cell. In an in vitro assay, the purified LexA protein bound to LEE promoters, which would prevent transcription by inhibition of binding to the RNA polymerase.

We have recently studied the involvement of RecA in resistance and virulence in A. baumannii. Although LexA is not present in this species, our results suggest the involvement of RecA in DNA repair through recombinatorial repair. A. baumannii recA mutants were 20 times more sensitive to macrophages than the parental strains. In an in vivo murine model, the mutant showed attenuated virulence, probably due to low survival in the host. Indeed, the recA mutant exhibited higher susceptibility to some β-lactams, colistin, trimethoprim-sulfamethoxazole, and fluoroquinolones than the wild-type parent strain. In this case, this protein directly links both virulence and antimicrobial resistance to a process of DNA repair (344). Similar studies have highlighted the importance of RecA as a regulator of virulence in S. Typhimurium (345), Pasteurella multocida (346), and Burkholderia spp. (347).

Mutator PhenotypesMutator (or hypermutable) strains are microorganisms that exhibit an increased mutation frequency due to a defective DNA repair system. The methyl-directed mismatch repair system (MutS, MutL, MutH, or UvrD) is the most frequently affected system in mutator populations (348). These mutator strains are known to have evolutionary advantages in new environments or stressful situations. Most of these mutations are neutral or even deleterious, but they may be favorable under directional selection (349, 350). For instance, under antibiotic pressure (351) or during infection (352), the mutator phenotype confers an advantage over the wild-type strain, thereby increasing its relevance as a clinical problem. Although the mutator strains can explore new ecosystems more quickly by increasing the rate of appearance of new mutations, this advantage disappears when the adaptation occurs. Even if the mutation rate is not reduced, the mutator strain may lose fitness over the long term (350) or in secondary environments after infection (352).

Although the prevalence of these phenotypes is variable, they are overrepresented in chronic infections caused by P. aeruginosa (353, 354, 355), S. aureus (356), and Haemophilus influenzae (357). In cystic fibrosis (CF), they are also frequently produced by hypermutable strains (strains more resistant than the nonmutator strains). In CF, the mutator strains of P. aeruginosa develop resistance to antipseudomonal antimicrobials much more frequently than nonmutators (353, 358), with efficient development of resistance through chromosomal mutation (359). Moreover, the persistence of P. aeruginosa in the lungs of CF patients results in changed resistance and altered virulence; acute injury is decreased, but chronic inflammation is increased, which promotes metabolic adaptation of the organism to the microaerobic conditions in the lungs of CF patients (360), usually leading to the loss of function of genes involved in virulence. It has also been observed, in a CF mouse model of chronic colonization, that the mutator strains favor long-term persistence; these strains compete with the wild-type strains, their fitness increases over time, and the numbers of adaptive mutations also increase (354). It has also been shown in this species that strains with a defective DNA repair system have enhanced microcolony-based growth, which is promoted by high biofilm production, thereby relating resistance and virulence (361). However, once again, because of the accumulation of multiple deleterious mutations in other, non-CF lung environments, adaptation to long-term persistence in CF-associated infection is not cost free. A reduction in transmission capacity was observed in that study; in a similar study with mutator isolates from CF patients, reduced virulence and fitness were observed on establishment of lung infection, suggesting a reduced potential for colonization of new environments (362).

Except in P. aeruginosa, the mutator isolates usually represent a low percentage of the population because of the burden of deleterious mutations. However, the mutators are sometimes linked to hypervirulent clones, as in the epidemic N. meningitidis serogroup A, which is the only serogroup capable of transcontinental spread and disease and which includes a high prevalence of isolates with elevated mutability. Richardson et al. showed that 57% of serogroup A isolates studied displayed elevated mutability, indicating the important role of this factor in the spread and evolution of serogroup A strains of N. meningitidis (363). A similar situation can be observed by contemplating the global distribution and success of the W-Beijing genotype of Mycobacterium tuberculosis, which is highly virulent and pathogenic. In a study of 55 W-Beijing isolates, most of the isolates carried missense mutations in mut genes, showing that successive alterations of the defective DNA repair systems may provide a selective advantage to the bacteria to adapt and persist, including resistance to antituberculosis drugs (364).

Hypermutation of strains of S. Typhimurium has also been studied in an in vivo mouse model, by comparing the fitnesses of wild-type and DNA repair-defective mutator strains. After 66 to 132 generations, the MICs of nalidixic acid and rifampin for the mutator strains were much higher than those for the wild-type strains, and in both types of strains the evolved populations of mice were fitter than the parental strain. In secondary environments, i.e., growing in LB medium under laboratory conditions, there was no general loss of fitness (measured as competition index [CI]) between the evolved and the parental populations. However, analysis of the capability to utilize various carbon sources showed that none of the wild-type lineages had lost any metabolic functions but that all the mutator strains had one or more defects. The authors of this study finally associated adaptation to the infection in mice by the mutators with a loss of fitness in secondary environments due to reduced metabolic capability (352). The role of the mutator phenotype in the pathogenesis of E. coli during chronic urinary tract infections was also shown in in vivo models (365).

In conclusion, hypermutation confers advantages such as the rapid acquisition of chromosomal resistance by antibiotic pressure, and it also enables modification of virulence and metabolism in order to persist in specific environments, although usually with a biological cost outside the primary environment.

Persister CellsPersisters are dormant variants of microbial populations that are tolerant to antimicrobials (not really resistant). They favor the recalcitrance of chronic infections to therapy and are more frequent in the biofilm state, which partly explains why it is difficult to treat infections caused by pathogens in biofilms. Persisters are particularly frequent in P. aeruginosa infections in patients with cystic fibrosis (366) and in Candida albicans infections in patients with oral thrush biofilm (367), although they have also been described in other species such as S. aureus (368) and E. coli (369).

Although the mechanism of antimicrobial tolerance in these subpopulations is not yet clear, it does not appear to operate at a mutational level. The SOS response (370, 371) and environmental stresses, such as oxidative stress (372), appear to be involved in the activation of persister formation. The tolerance involves overproduction of several toxin/antitoxin systems, such as RelE, which inhibits translation, thus preventing the lethal action of aminoglycosides to act over protein synthesis (373), as well as TisAB, a DNA damage-induced toxin that promotes the production of ciprofloxacin-tolerant cells (374), and HipAB, other toxin/antitoxin system involved in blocking translation and tolerance to different antibiotic families (371). Induction of the AcrAB-TolC efflux pump, by means of oxidative stress, also increases the production of quinolone-tolerant persister cells (372).

Overall, the data summarized above show that persistent subpopulations are a clear example of how pathogenic populations can evolve and adapt to survive and persist in the environment. In such antimicrobial-tolerant populations, which are difficult to eradicate, tolerance is closely linked to the expression of different virulence factors.

Alarmone Guanosine TetraphosphateThe guanosine tetraphosphate alarmones, which are intracellular signaling molecules collectively known as (p)ppGpp, are a clear link between antibiotic resistance and virulence. Levels of (p)ppGpp are correlated with the expression of virulence traits, including survival of stress in bacteria such as Campylobacter jejuni, Brucella abortus, Streptococcus mutans, and Bacillus subtilis (375 – 378), biofilm formation in E. coli, S. mutans, and Listeria monocytogenes (377, 379, 380), antibiotic resistance in E. coli and Brucella abortus (376, 381 – 383) and infection persistence in M. tuberculosis, S. mutans, and E. coli (376, 381, 384 – 387). In some cases, animal models have provided unequivocal evidence of the role of (p)ppGpp in stress responses, vancomycin tolerance, and virulence in E. faecalis (388). It is not yet clear whether (p)ppGpp plays a direct role in the expression of genes that confer vancomycin tolerance to E. faecalis or if it initiates a regulatory cascade that leads to tolerance. Until recently, bifunctional RelA was considered the only enzyme responsible for controlling (p)ppGpp metabolism in Gram-positive bacteria. However, two related small enzymes, designated RelP and RelQ, were recently identified and shown to function as true alarmone synthetases in S. mutans, S. pneumoniae, and B. subtilis (389 – 391). Recent studies have revealed that bacteria have evolved different modes of (p)ppGpp regulation and that the effects of (p)ppGpp on cell physiology vary greatly among different organisms (390 – 392). Abranches et al. studied the inhibitory concentrations of vancomycin for E. faecalis and found that the MIC was the same for the relA mutant and the wild-type strain and also that the mutant strain grew faster in the presence of subinhibitory concentrations of the drug and survived better in time-kill studies. However, vancomycin MICs for the relQ and relAQ strains were lower and growth of these strains was slower or impaired in the presence of subinhibitory concentrations, and they were killed more rapidly by vancomycin; these characteristics were more pronounced in the relAQ strain (388). The findings confirm the involvement of these enzymes in the control of metabolism of the ppGpp molecules (Fig. 9).

Fig 9
  • Open in new tab
  • Download powerpoint
Fig 9

Growth curves and time-kill curves for E. faecalis OG1RF, relA mutant [relA encodes an enzyme responsible for controlling (p)ppGpp metabolism in Gram-positive bacteria], relQ mutant (relQ encodes an enzyme related to constitutive expression of ppGpp in nonstressed cells), and relAQ double mutant strains in the presence of subinhibitory concentrations of vancomycin (386, 390). (A) Growth curves reveal that the relA mutant grows faster than E. faecalis OG1RF (a strain harboring the ebp gene, which encodes endocarditis and biofilm formation-associated pilus operon). However, relQ and relAQ mutants strains display slow or impaired growth in the presence of vancomycin. (B) Time-kill curves reveal that the relA mutant survives better than the relQ and relAQ mutants, which were killed more rapidly by vancomycin. (Reprinted from reference 388 with permission.)

However, these mechanisms are better characterized in other bacteria, such as S. aureus and E. coli. Gao et al. (393) carried out a comparative and functional genomic study of sequential S. aureus isolates from a patient with persistent and recurrent S. aureus infection after therapy with multiple antimicrobials (including linezolid) had failed. The results showed that the mutations in relA caused accumulation of (p)ppGpp, which was associated with reduced growth and attenuated virulence in the G. mellonella model; furthermore, mutations in rlmN (encoding a ribosomal methyltransferase that methylates 23S rRNA at position A2503) caused a reduction in linezolid susceptibility. The association between (p)ppGpp levels and resistance to antibiotics has been observed in E. coli. It has been demonstrated that artificially raising (p)ppGpp levels increases β-lactam tolerance in E. coli (382), and mutant cells lacking RelA are more susceptible to β-lactams (383). In the latter case, resistance to microcin J25 was shown to involve (p)ppGpp-dependent induction of an efflux pump responsible for lowering the intracellular level of the peptide (383).

In a comparison of genomic and functional markers in strains of S. aureus in a patient with persistent and recurrent infections, mutations were detected in two genes, relA and rlmN. The mutation in the relA gene was associated with accumulation of the intracellular signaling molecule alarmone guanosine 3′,5′-bis(diphosphate) (ppGpp) and permanent activation of the stringent response. The second mutation found in rlmN, which encodes a ribosomal methyltransferase that also methylates the 23S rRNA at position A2503, caused a reduction in linezolid susceptibility. These results show the capacity of adaptation of S. aureus and also how subtle molecular changes cause major alterations in bacterial behavior (393).

Alternative Sigma Factor σB The alternative sigma factor σB modulates the general stress response in certain Gram-positive bacteria, including S. aureus, B. subtilis, and L. monocytogenes (394). In S. aureus, alternative sigma factor σB controls the expression of multiple genes, including virulence determinants such as α-hemolysin (encoded by hla), fibronectin-binding protein A (encoded by fnbA), and global regulators (SarA and/or Agr locus); it also promotes capsule production (395) and increases the resistance levels of methicillin-resistant S. aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains (396, 397). It has recently been shown that inactivation of the staphylococcal factor σB-controlled yabJ-spoVG operon, which codes for B. subtilis YabJ and SpoVG sequence homologs, significantly reduces the level of transcription of the cap operon and impedes capsule formation in capsular polysaccharide-producing strains (398). Schulthess et al. (396), showed that deletion of the factor σB-dependent yabJ-spoVG operon in MRSA and GISA strains decreased the resistance levels in a similar way as observed for the deletion of factor σB, suggesting that factor σB exerts its effect on methicillin and glycopeptide resistance via the gene products of the yabJ-spoVG locus, in particular, via SpoVG. It remains to be determined which of the multiple chromosomal genes affecting methicillin or glycopeptide intermediate resistance levels are controlled by the factor σB-SpoVG cascade. In L. monocytogenes, σB proteins have also been associated with the vancomycin stress response. Factor σB may contribute to monitoring and maintaining cell wall integrity by regulating certain genes and factors that are important in stress responses, cell metabolism, and virulence (399).

NOVEL ANTIVIRULENCE THERAPIES: MECHANISMS OF RESISTANCE TO ANTIVIRULENCE COMPOUNDS

Antivirulence therapies are based on inhibition of bacterial virulence and do not affect bacterial growth; those antivirulence compounds can be administered in combination with antibiotic treatment, thereby decreasing the selective pressure on bacteria and preventing the development of resistance to these antibiotics (400). Inhibition of the following mechanisms of virulence enables interruption of colonization and infection processes or of the development of bacterial infection: toxin production, adhesion, bacterial secretory systems, cell-to-cell signaling, iron metabolism, and virulence mechanisms involved in the host immune response and antibiotic resistance (Table 3). Of all the antivirulence compounds included in Table 3, we will comment on several compounds from two groups (cell-to-cell signaling inhibitors and RND efflux pump inhibitors) because of their involvement in resistance and virulence.

View this table:
  • View inline
  • View popup
Table 3

Antivirulence compounds

Cell-to-Cell Signaling InhibitorsBacteria were previously thought to act independently of stimuli. However, more recent studies show that bacteria can communicate with each other through complex signaling networks (400). Molecules that act by inhibiting this mechanism have been described. A couple of examples are as follows. (i) Compounds that inhibit the expression of virulence genes and also have a synergistic effect on the bactericidal action of certain antibiotics are beginning to appear, e.g., the compound tomatidine, which displays the effector-enhanced bactericidal action of aminoglycosides and also inhibits the expression of virulence genes linked to the Agr system in strains of S. aureus that are susceptible and resistant to various antimicrobials (403). (ii) The new quaternized chitosan derivative hydroxypropyltrimethyl ammonium chloride chitosan with a 26% degree of quaternary ammonium substitution (26%HACC) displays strong antibacterial activity against Staphylococcus spp. and simultaneously good biocompatibility with osteogenic cells. It was found that 26%HACC-loaded polymethylmethacrylate (PMMA) markedly downregulated the expression of icaAD, which encodes essential enzymes for polysaccharide intercellular adhesion biosynthesis, upregulated the expression level of icaR, which negatively mediates icaAD expression, and also downregulated the expression of mecA, which encodes membrane-bound enzymes known to be penicillin-binding proteins. Hence, the 26%HACC-loaded PMMA prevents biofilm formation by Staphylococcus spp., including methicillin-resistant strains, on the surface of bone cement and downregulates virulence-associated gene expression of antibiotic-resistant Staphylococcus spp., thus providing a promising new strategy for combating implant infections and osteomyelitis (402).

RND Efflux Pump InhibitorsRND efflux pumps play a role in the pathogenicity of bacteria, and they mainly affect colonization, infection, and the persistence of microorganisms in the host (66). Moreover, these efflux pumps are involved in the QS-regulated expression of virulence determinants (68). Several RND pump inhibitors have been described. We analyze two examples: (i) The 1-(1-naphthylmethyl)-piperazine (NMP) and phenyl-arginine-β-naphthylamide (PAN), which act as inhibitors of RND efflux pumps and virulence factors in Vibrio cholerae, such as the cholera toxin and the toxin-coregulated pilus (404), have been suggested as a useful tool for the treatment of cholera infections. (ii) Of 12 trifluoromethyl ketone compounds tested, 6 proved to be effective inhibitors of the quorum-sensing response by Chromobacterium violaceum 026, as well as inhibitors of the RND efflux pumps of CV026 and E. coli. This finding is of clinical relevance and may be exploited for the prevention of QS responses of infecting bacteria (401). Inhibitors of efflux pump systems have therefore been suggested as a useful tool for the treatment of cholera infections.

Antimicrobial Compounds with Antivirulence ActivitySome studies have investigated the antivirulence activity of antibiotics such as azithromycin (macrolide), linezolid (oxazolidinones), rifampin, and ciprofloxacin. Azithromycin and rifampin present a clear anti-inflammatory activity; however, in recent years there have been publications showing the antivirulence activity of these compounds. Kohler et al. associated azithromycin treatment with inhibition of QS in P. aeruginosa infections, which presents a clinical benefit for the patient. However, the authors commented that if the treatment is discontinuous, there is an increased risk of colonization by highly virulent bacteria, which highlights the need to study the positive and negative implications of antivirulence therapies (405). Azithromycin has been shown to improve pulmonary function without reducing the number of bacteria. It is known that in the development of P. aeruginosa infection, the pathogen releases virulence factors that affect the epithelial integrity, thus exposing the epithelium to additional bacterial infiltration. Administration of azithromycin in patients with cystic fibrosis attenuated the effect on epithelial integrity (406). On the other hand, in a recent study with animal models, it was shown that treatment with azithromycin inhibits intracellular killing of multidrug-resistant nontuberculous mycobacteria (NTM) within macrophages. The authors concluded that azithromycin blocks the development of autophagy by promoting the development of persistent infections by NTM (mainly M. abscessus) in patients with cystic fibrosis (407). Rifampin can attenuate the cellular damage induced by multidrug- and pan-drug-resistant A. baumannii clinical isolates without being significantly bactericidal. Indeed, the cytoprotective effect of rifampin was observed as a decrease in the number of dead cells induced by A. baumannii, achieved by reducing oxidative stress and proinflammatory cytokine release (408).

In relation to linezolid (LZD), one study examined the application of subinhibitory concentrations that suppress virulence factors in methicillin-resistant S. aureus infections, which may be associated with a reduction of endogenous pyrogens. This may at least partly explain early defervescence observed in LZD-treated individuals (409). Moreover, systemic treatment with LZD has recently been shown to have an inhibitory effect on biofilm development in methicillin-resistant S. aureus (MRSA) infection of the endotracheal tube (410). Finally, ciprofloxacin associated with lytic bacteriophages has been used in the treatment of the K. pneumoniae infections. The combination treatment not only killed the bacteria but inhibited biofilm formation and significantly restricted the formation of resistant variants in comparison with individual treatments (411).

In vitro experiments have shown that the application of probiotic isolates of Lactobacillus rhamnosus GG prevents invasion of the upper respiratory tract by group A macrolide-resistant streptococci carrying the prtF1 gene, which encodes fibronectin (Fn)-binding F1 invasion (412). This effect is due to competition between L. rhamnosus GG and group A macrolide-resistant streptococci for Fn binding in the inhibition process, which confirms the antagonistic action of L. rhamnosus GG against group A streptococci.

Resistance to Antivirulence ComponentsTo date, the only known study of the mechanism of resistance to antivirulence components is that by Maeda et al. concerning resistance to furanone C-30 (99). Furanones interact with the transcriptional regulator descending signal LASR acyl homoserine lactone and therefore attenuate the virulence in a pulmonary infection model of P. aeruginosa in mice. The authors worked with mutants of the mexR and nalC genes, which are negative regulators of the MexAB-OprM efflux pump, and observed expulsion of compound C-30 by the MexAB-OprM efflux pump in the mutants (Fig. 10). Furthermore, the results were confirmed in the Liverpool epidemic strain (overexpression of MexAB-OprM, nalC and mexR mutants), which is known to increase morbidity in patients with cystic fibrosis (98, 413). On the other hand, a mexA mutant with reduced MexAB-OprM efflux pump activity was previously found to be less virulent in a pathogenesis model (P. aeromonas and C. elegans) (414). Moreover, Maeda et al. reported that the mexR mutant (with enhanced MexAB-OprM efflux pump activity) is as virulent as the wild-type strain and is much more virulent in the presence of the QS inhibitor (C-30) than the wild-type strain (99).

Fig 10
  • Open in new tab
  • Download powerpoint
Fig 10

The mexR and nalC mutations decrease C-30 inhibition of P. aeruginosa QS phenotypes. (a) Swarming motility. The rhlR mutant (rhlR encodes the two transcriptional regulators of the acyl homoserine lactone system of P. aeruginosa) was used as a negative control. MeOH was used as a negative control for C-30. (b) Production of pyocyanin (phenazine toxic metabolites). An asterisk indicates statistical significance. A PA14 phz mutant (a strain without phenazine production) was used as a negative control. (Reprinted from reference 99 by permission from Macmillan Publishers Ltd.)

DISCUSSION

Finally, we address the following series of questions and reflections that arise in relation to the prospects in the near future.

How Does Increased Antimicrobial Resistance Affect Virulence?Throughout this review we have examined some examples of the most important factors that affect the complex process of bacterial evolution, specifically the evolution of antibiotic resistance and virulence. There are no general solutions to this puzzle, and the association between virulence and resistance in a specific pathogen will depend on the interactions between the multiple factors associated with bacteria and their environments.

The final effect (whether positive or negative) of the association between bacterial virulence and antimicrobial resistance depends mainly on four factors. (i) The first factor is the bacterial species. Some microorganisms readily acquire antibiotic resistance mechanisms and evolve rapidly in response to antibiotic pressure (e.g., P. aeruginosa and A. baumannii). However, others remain fully susceptible to penicillin, although this has long been the treatment of choice for infections caused by the particular pathogen (e.g., S. pyogenes). Therefore, in the first type of bacteria, virulence will be more greatly influenced by the acquisition of resistance. (ii) The second factor is specific virulence and resistance mechanisms. These are involved in both processes at the same time (e.g., the AcrAB-TolC efflux pump of E. coli, which expels fatty acids and bile salts and also antibiotics) (415, 416) or are involved indirectly (e.g., the PhoP-regulated resistance to colistin in P. aeruginosa, which causes changes in the LPS and loss of affinity and is simultaneously involved in a decrease in virulence via lower biofilm production and lower cytotoxicity) (197). (iii) The third factor is the environment or ecological niche. This factor largely determines the development of the infection. Clear examples include the following: two-component systems, which regulate virulence and resistance at the same time and which depend on external stimuli; the presence/absence of specific molecules (e.g., depletion of iron during the course of an infection in the host); the antibiotic concentration, which depends on the anatomical site of an infection; and a high NaCl concentration in the environment, which in A. baumannii may trigger a response that increases the resistance to several antibiotics through upregulation of efflux pumps and release of outer membrane proteins involved in virulence (417). (iv) The fourth factor is the host (the immune system). Although in the strictest sense the host apparently does not affect the virulence of a pathogen, the host/pathogen interaction is key in the development of an infection and therefore in how the acquisition of resistance affects virulence.

The concentration of antibiotics in an environment will determine the importance of the antibiotic pressure on bacterial evolution in that niche, and selection will be directed toward the success of the most resistant pathogens. However, during colonization and infection, the most virulent pathogens will be the most successful and will therefore be the most likely to survive. Emergence of antibiotic resistance in a bacterial population is related to different factors, the following of which are critical: the rate of mutation toward resistance, the acquisition of horizontally transmitted genes, and the fitness cost to the bacteria. If resistance implies a fitness cost for the microorganism, the growth rate would not be sufficient to compete with the fitness of susceptible bacteria, with the killing mediated by immune system cells, or with the dynamics of the body fluids during the process of colonization or infection. The fitness cost of the mechanism and the possibility of being selected through the coselection process will have a strong impact on the success of the selection. Note that we are not considering another factor here, the epidemicity, or the capacity to survive/persist and disseminate in specific environments, which may deserve by itself further review.

Thus, in a nosocomial environment, resistant and/or virulent bacteria (coselection) may be readily selected as a result of selective antibiotic pressure, and the effect of the biological cost of the resistance mechanism is secondary to the strong antibiotic pressure. However, the situation is different in the community environment. In environments in which there is no direct selective antibiotic pressure (low concentrations of antibiotics), increased resistance will probably have a negative effect on the relationship between resistance and virulence, and if the biological cost of this mechanism is high, the mechanism will tend not to be selected.

What Are the Perspectives in the Near Future in Relation to Antimicrobial Resistance and Virulence?Our current knowledge of the world of pathogenic microbes is possibly only the tip of the iceberg. Most basic studies seek direct solutions to major clinical problems and overlook the genetic backgrounds of most microorganisms that are not directly involved in infectious processes. Thus, for example, most structural and phylogenic studies on plasmids are performed with clinical isolates or isolates with antimicrobial resistance mechanisms, and those not associated with clinical environments are disregarded. This leads to a huge bias in our knowledge of plasmid biology and our understanding of the dissemination of antimicrobial resistance. The explosion of new molecular techniques in the last decade will gradually allow us to overcome this bias and obtain a much broader view of the microbial world, which will lead to a better understanding of the specific interactions between resistance and virulence and bacterial functioning in general.

Regarding what we can expect in the near future, we must consider how bacterial virulence evolved prior to the presence of large amounts of antibiotics in the environment. When low concentrations of antibiotics were in nature, those antibiotics probably had a small effect on bacterial resistance/virulence. However, this scenario changed dramatically in the 1940s, when antibiotics began to be used widely in clinical practice; the evolution of virulence has been greatly affected by the indiscriminate use of antibiotics and has probably moved irreversibly in a new direction. The development of virulence factors and the evolution of resistance determinants in pathogens overlap considerably, and it is difficult to consider them as independent processes. It is important to emphasize the global impact on the microflora, including the human microflora. The huge amounts of antibiotics used in virtually all environments (223) cause displacement (input of exogenous antibiotic-resistant bacteria) or modification (antibiotic-resistant mutants) of the microflora. Globally, the nonpathogenic species, commensals, are now less susceptible than before (3), regardless of their ecological niche. Moreover, strains that are poorly adapted or poor colonizers of new niches, but which are resistant, are now more likely to replace those well-adapted or colonizing species that are more susceptible to the presence of antibiotics (418). The impact of these changes on human health is so far unknown.

Thus, microorganisms, such as opportunistic pathogens, are able to compete in new niches where previously only commensals or nonpathogenic microorganisms existed. One clear example of this is the appearance in the past decades of opportunistic nosocomial pathogens (e.g., P. aeruginosa and A. baumannii) that are not capable of producing infection in healthy hosts but display a high capacity to survive, persist on surfaces (invasive equipment, etc.), and adapt to the nosocomial environment, where they may cause infection in patients with weakened immune systems. The ability to acquire antibiotic resistance is one of the main characteristics of such species. Other pathogens, such as E. coli as an example among others, do not acquire resistance to antibiotics as readily (the relative prevalence of A. baumannii or P. aeruginosa in hospital settings is currently increasing at a greater rate than that of E. coli). The capacity to develop or acquire resistance and the ability to persist in complicated “hostile” environments are key factors in explaining the increment in the number of infections at least in hospitalized patients. Jawad et al. concluded that in A. baumannii, both desiccation tolerance and MDR phenotype may contribute to the maintenance of this species in the hospital setting and may partly explain its propensity to cause prolonged outbreaks of nosocomial infections (419). This is a typical example of a microorganism in which the clinical importance parallels the increase in antibiotic use and selection of resistance strains. Once the fitness cost of the resistance mechanisms is compensated if necessary with compensatory mutations, these pathogens can probably also increase their virulence by acquiring new virulence factors, as in, e.g., A. baumannii. Thus, we must consider the following, at least taken as example with A. baumannii. Are more infections already caused by A. baumannii? Are these strains more resistant? Are these strains more virulent? Probably, and considering the difficulties in providing a convincing and rational response to these questions, affirmative answers to the three questions can be considered. To date, there are probably more A. baumannii infections (we can simply search the appropriate keyword in PubMed to get an approximate idea of the increasing numbers of infections and nosocomial outbreaks), and the strains often are more virulent; these processes are linked as a result of coselection and coevolution (44). More infections are already occurring because A. baumannii has adapted to living in the presence of antibiotics, and furthermore, it has evolved to cause greater damage to hosts in order to survive inside the host and hospital environments (44). Apart from specific examples like this, the effects that these changes will have on human health are so far unknown. However, if this hypothesis is correct, microbiological studies in the near future will show whether or not A. baumannii is becoming more virulent and more resistant.

Bearing in mind that antibiotics are present in the vast majority of bacterial niches on the planet and that we are unlikely to stop using these compounds, resistance does not appear to be reversible, although it is an increasingly urgent problem (420). Given the huge number of bacterial generations that occur within during a single human generation, it seems unlikely that the limited arsenal of antibiotics available at present or that is likely to be available in the immediate future can compete in biological terms with the enormous capacity for bacterial pathogens to evolve and change (421, 422). Clearly, microorganisms will be increasingly resistant in the future. However, will they be more virulent? In this review we have discussed numerous examples of the association between virulence with resistance, which can be positive or negative, with the final balance determined by the ability of the bacterium to survive or adapt in a specific ecological niche. However, the huge genetic arsenal that bacteria can make use of to compensate for or overcome the fitness costs suggests that in the near future virulent and resistant clones will emerge simultaneously. Processes that favor bacterial success include coselection (in same MGE, plasmids, transposons, islands, etc.) of the ability to spread resistance and virulence genes, along with compensatory mutations, hypermutation (which favors the development of both processes), and the effect of SOS-inducing antimicrobial agents (such as quinolones).

Genetic mechanisms that spread resistance genes often encode resistance to different families of antibiotics, which means that the withdrawal of a family of antibiotics would not cause the reduction or disappearance of strains resistant to that family (423). Carrying virulence genes also confers on bacteria some evolutionary advantage during the colonization and infection processes, which thus favors the resistant strains. This plasticity provides pathogens access to new strategies to explore new environments in which the normal microflora would be at a disadvantage. There are clear examples of the worldwide distribution of highly epidemic multiresistant clones that are selected mainly as a result of encoded multiresistance; these are the so-called high-risk clones, such as the KPC carbapenemase-positive K. pneumoniae ST258 clone, the E. coli ST131, ST38, ST393, and ST405 clones, which usually carry CTX-M-15 β-lactamase, and the carbapenem-resistant ST175 and O12 clones of P. aeruginosa (202, 203, 424). These clones are extremely well adapted to new environments with a high presence of antibiotics, and they are often more virulent. The PMEN1 clone of S. pneumoniae, which is distributed worldwide, is resistant to chloramphenicol and tetracycline, and many isolates are also resistant to fluoroquinolones and macrolides; the genome encodes several virulence factors, including the blp bacteriocins and cell wall surface-anchored proteins (210). Another example is the multiresistant and virulent Liverpool epidemic strain of P. aeruginosa in patients with cystic fibrosis (98, 425, 426). We note that the resistance of all these MDR clones with this genetic arsenal is increasing as a result of the so-called genetic capitalism concept, in which resistant organisms tend to become even more resistant (427). In addition to the importance of coselection, we highlight the role of compensatory mutations in fitness costs. It is relatively easy for bacteria to compensate for the increased fitness cost associated with new resistance, as resistant pathogens are able to maintain (via compensatory mutations, for example) this resistance and additionally retrieve or even increase their fitness. Therefore, compensatory evolution could stabilize resistant populations, even in the absence of antibiotics, so that they will be able compete with the other commensal microflora on equal terms. These compensatory mechanisms usually follow one of the three above-described strategies, and alternative mechanisms are used for the same function, thus reducing the need to carry out the function and restoring its effectiveness. Although the role of these compensations in the stability of resistant bacterial populations outside the laboratory is not yet clear, some authors have identified such mechanisms in the clinical environment and have recognized this as a potential problem in the coming years with the current treatments used (278).

Are There Alternatives to Antimicrobial Therapy for Controlling Bacterial Multiresistance and Virulence?When analyzing the prospects for the future, the urgent need for new antibiotics to treat emerging bacteria that are resistant to almost all antibiotics (extremely drug resistant [XDR]) should be taken into consideration. No truly new antibiotics have been developed against Gram-negative pathogens that have emerged since the 1990s. There is clearly a need to develop and market new antibiotics or compounds capable of increasing permeability in bacteria or of evading efflux and avoiding mutational resistance, among other approaches (428).

The development of innovative antivirulence therapies as a new way to combat resistant and/or virulent pathogens is a promising alternative to conventional antimicrobial treatment. An example is the proanthocyanidins, used in clinical practice, whose mechanism of action is based on binding to the filaments or fimbriae of E. coli and other bacteria in the urine and preventing these bacteria from adhering to the walls of the lower tract mucosa. The proanthocyanidin intake type helps to prevent recurrence infections, as recent studies show (429).

Several reviews that address new virulence inhibitors, both in vivo and in vitro, have been published. Moreover, many of these antivirulence compounds are capable of inhibiting the virulence of different species that have a common mechanism of virulence. Theoretically, the use of antivirulence therapies directed exclusively against such virulent microorganisms would avoid acting against nonvirulent bacteria. This approach would therefore lead to preservation of susceptible nonpathogenic bacteria, which would act as a barrier for colonization by virulent populations; antibiotic pressure would also be lowered, thus minimizing the risk for horizontal spread of drug resistance genes (430, 431). The combined use of antibiotic therapy and antivirulence compounds could become an effective alternative within a few years (400, 420, 432). However, as with antibiotics, resistance to antivirulence compounds has already emerged, such as to furanone through increased expression of the MexAB-OprM efflux pump in the multiresistant and virulent Liverpool epidemic strain of P. aeruginosa (413). Finally, we highlight the antivirulence activity of some already commercialized antimicrobials, such as rifampin against A. baumannii (408), subinhibitory concentrations of linezolid against S. aureus (409), and azithromycin, a macrolide that exhibits antibacterial activity against P. aeruginosa and has also displayed antivirulence activity and anti-quorum-sensing activity (decreasing virulence and cooperation) (405, 406). Further studies of antibiotic activities other than bactericidal or bacteriostatic activities are required, as these could help in the development of new antimicrobial therapies for the treatment of infectious diseases.

It is interesting to note the possible role that vaccines may play in the evolution of pathogenic bacteria in the near future. Advances in our understanding of the immune response and molecular biology suggest that in coming years, we will witness a major advancement in the development and emergence of numerous vaccines (433). The long-term impact of vaccines would theoretically decrease populations of pathogens, thus reducing the possibility of the development of new mechanisms of resistance, either by new mutations or by horizontal transmission from other resistant pathogens. However, it is possible that in the long term, the clones/serotypes used in these vaccines may be displaced by other clones, present in low numbers prior to introduction of the vaccine and prevalent after its use. This is of some concern, and the selection of virulent serotypes has already been reported. In Utah, the number of cases of necrotizing pneumococcal pneumonia increased after the introduction of the seven-valet pneumococcal conjugate vaccine (PCV7). The prevalence of the non-PCV7 serotype was 49% before the use of the vaccine and increased to 88% after the introduction of PCV7; between these prevalences was that of serotype 3, which is associated with necrotizing pneumococcal pneumonias (434). Therefore, in addition to antibiotic pressure, the use of vaccines will exercise an increasing and important selective pressure on bacterial evolution, especially among the pathogenic microorganisms; whether both pressures will jointly exercise selection is still unknown. One promising alternative is the use of vaccines that specifically target strains or clones that are particularly important from a clinical point of view, such as MDR epidemic clones (i.e., E. coli ST131 or K. pneumoniae ST258) or virulent and resistant clones (i.e., the S. pneumoniae PMEN1 clone and the Liverpool epidemic strain of P. aeruginosa [LES]). Development of vaccines with epitopes that are conserved among strains of these specific traits would enable us to combat the emergence of these high-risk clones without damaging nonpathogenic commensal microorganisms. Thus, Wieser et al. have recently developed a vaccine in mice against extraintestinal pathogenic E. coli (ExPEC), which may be cost-effective for use in selected patient groups and is based on epitopes of several virulence-associated ExPEC proteins (435). Other alternatives are not discussed in the present review, as they are probably out of our aim here.

Are Antibiotic Resistance and Virulence Increasingly Linked in the Development of Infectious Processes?Although most microbiological studies focus separately on virulence or resistance, the relationship and mutual biological impact of one event on the other is increasingly being studied. On writing this review, we realized that the joint detailed analysis of both processes will provide a better understanding of the relationship between virulence and antimicrobial resistance. Similarities become apparent when these processes are investigated together. Fundamentally, virulence is directly associated with the development of resistance from the point of view that (theoretically) just when the host shows clear signs of infection or disease (i.e., when the virulent pathogens are present), antibiotic therapy is administered; however, in the absence of infection (the normal flora of the host, without pathogenic microorganisms), exposure to antibiotics is probably much lower, so that the possibility of developing resistance due to the lack of antimicrobial pressure is also lower.

We have discussed two alternative scenarios in this review. Thus, in some cases increased resistance is accompanied by increased virulence, as in the following examples: in plasmids carrying both factors (229, 237, 436); during activation of the SOS system, which facilitates the spread of the resistance- and virulence-encoding genes at the same time (336, 337); and with accumulation of alarmones in E. coli, which is associated with biofilm formation and tolerance to β-lactams, among some others (382). However, in other examples, the increased antimicrobial resistance reduces the virulence (or fitness cost) of the microorganisms: during the acquisition in E. coli of β-lactamases, such as OXA-10, OXA-24, and SFO-1 (in which changes in the peptidoglycans have a fitness cost and thus explain the low incidence of some β-lactamases in this species) (34), and the fitness cost associated with the acquisition of vancomycin resistance in methicillin-resistant S. aureus (167), among many other examples. There is also a third option, in which there is apparently no significant effect on the virulence, such as the acquisition of the β-lactamases CTX-M-1, TEM-1, and CTX-M-32 in E. coli (32, 34) or of the bla IMP metallo-β-lactamase in P. aeruginosa (33). The regulatory two-component systems in many bacterial pathogens, such as S. aureus, represent a clear example of the link between resistance and virulence (395, 396). Such associations also occurred prior to the massive use of antibiotics, so that in the future (with the development of new molecular biology techniques), new signs of these relationships could be identified.

This association between resistance and virulence follows a Darwinian model, in which those traits that confer a specific advantage will be selected (sooner or later) and become fixed. Those associations with a positive effect (increased resistance plus increased virulence) will be selected very rapidly. Those in which selection is apparently negative (i.e., increased resistance correlated with diminished virulence) will undergo a longer selection process, until a specific virulence advantage is selected and becomes fixed in the population. The opposite may also occur, so that increased virulence will lead to decreased resistance. In this case, compensatory mutations may arise to equilibrate the balance, and increased resistance and virulence will finally proceed together to confer the bacteria with a selective advantage. Unfortunately for humankind, this is merely a matter of time, as with all evolutionary processes. To face this threat, further in-depth studies are necessary to investigate this association, and new nonantimicrobial therapies are necessary to attempt to control the emergence of high-risk clones in multiple pathogenic species in the near future. Indeed, future trends in clinical microbiology laboratories should include identification of pathogens and susceptibility analysis but should also include the development of molecular techniques and identification of high-risk clones or known virulent or epidemic clones (such as the E. coli ST131 clone, S. aureus USA300, and the Liverpool clone of P. aeruginosa [LES]), along with the development of tests for the rapid detection of the most important virulence markers.

ACKNOWLEDGMENTS

We thank Ana Fernández, Clara Povoa, Astrid Pérez, and Carmen Gayoso for their help in composing the figures.

Research in our laboratory is supported by grants from the Instituto de Salud Carlos III, the Spanish Network for Research in Infectious Diseases (REIPI RD 12/0015/0014), the Fondo de Investigaciones Sanitarias (PI08/1368, PS09/00687, and PI12/00552 to G.B. and PI10/00056 to M.T.), SERGAS (PS07/90), and the Xunta de Galicia (07CSA050916PR). A.B. is supported by the Secretaria de Estado de Investigación, Desarrollo e Innovación (program Juan de la Cierva), and M.T. is supported by the Instituto de Salud Carlos III (program Miguel Servet), both from the Ministerio de Economia y Competitividad.

  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Madigan MT,
    2. Martinko JM,
    3. Dunlap PV,
    4. Clark DP
    . 2009. Brock biology of microorganisms, 12th ed. Pearson Education Inc., Upper Saddle River, NJ.
  2. 2.↵
    1. Feldman MW,
    2. Laland KN
    . 1996. Gene-culture coevolutionary theory. Trends Ecol. Evol. 11:453–457.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Martínez JL,
    2. Baquero F
    . 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647–679.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Burrus V,
    2. Waldor MK
    . 2004. Shaping bacterial genomes with integrative and conjugative elements. Res. Microbiol. 155:376–386.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Handel A,
    2. Regoes RR,
    3. Antia R
    . 2006. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput. Biol. 2:e137. doi:10.1371/journal.pcbi.0020137.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Patel R
    . 2005. Biofilms and antimicrobial resistance. Clin. Orthop. Relat. Res. 437:41–47.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Seral C,
    2. Van Bambeke F,
    3. Tulkens PM
    . 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin LY333328 activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283–2292.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Barbosa TM,
    2. Levy SB
    . 2000. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J. Bacteriol. 182:3467–3474.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Tsai YK,
    2. Fung CP,
    3. Lin JC,
    4. Chen JH,
    5. Chang FY,
    6. Chen TL,
    7. Siu LK
    . 2011. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob. Agents Chemother. 55:1485–1493.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Moya B,
    2. Juan C,
    3. Alberti S,
    4. Perez JL,
    5. Oliver A
    . 2008. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 52:3694–3700.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Yeung AT,
    2. Bains M,
    3. Hancock RE
    . 2011. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa . J. Bacteriol. 193:918–931.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lye DC,
    2. Earnest A,
    3. Ling ML,
    4. Lee TE,
    5. Yong HC,
    6. Fisher DA,
    7. Krishnan P,
    8. Hsu LY
    . 2011. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin. Microbiol. Infect. 18:502–508.
    OpenUrlPubMed
  13. 13.↵
    1. Andersson DI,
    2. Levin BR
    . 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489–493.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Andersson DI,
    2. Hughes D
    . 2011. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol. Rev. 35:901–911.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Rudkin JK,
    2. Edwards AM,
    3. Bowden MG,
    4. Brown EL,
    5. Pozzi C,
    6. Waters EM,
    7. Chan WC,
    8. Williams P,
    9. O'Gara JPRC,
    10. Massey
    . 2012. Methicillin resistance reduces the virulence of healthcare-associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum sensing system. J. Infect. Dis. 205:798–806.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Pozzi C,
    2. Waters EM,
    3. Rudkin JK,
    4. Schaeffer CR,
    5. Lohan AJ,
    6. Tong P,
    7. Loftus BJ,
    8. Pier GB,
    9. Fey PD,
    10. Massey RC,
    11. O'Gara JP
    . 2012. Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog. 8:e1002626. doi:10.1371/journal.ppat.1002626.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Queck SY,
    2. Khan BA,
    3. Wang R,
    4. Bach TH,
    5. Kretschmer D,
    6. Chen L,
    7. Kreiswirth BN,
    8. Peschel A,
    9. Deleo FR,
    10. Otto M
    . 2009. Mobile genetic element-encoded cytolysin connects virulence to methicillin resistance in MRSA. PLoS Pathog. 5:e1000533. doi:10.1371/journal.ppat.1000533.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hicks LA,
    2. Chien YW,
    3. Taylor TH,
    4. Haber M,
    5. Klugman KP
    . 2011. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States. 1996–2003. Clin. Infect. Dis. 53:631–639.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Rieux V,
    2. Carbon C,
    3. Azoulay-Dupuis E
    . 2001. Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae . J. Infect. Dis. 184:66–72.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Zapun A,
    2. Contreras-Martel C,
    3. Vernet T
    . 2008. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev. 32:361–385.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Azoulay-Dupuis E,
    2. Rieux V,
    3. Muffat-Joly M,
    4. Bedos JP,
    5. Vallee E,
    6. Rivier C,
    7. Isturiz R,
    8. Carbon C,
    9. Moine P
    . 2000. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob. Agents Chemother. 44:1575–1577.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Fernandez A,
    2. Cabellos C,
    3. Tubau F,
    4. Linares J,
    5. Viladrich PF,
    6. Gudiol F
    . 2001. Relationship between penicillin and cephalosporin resistance of Streptococcus pneumoniae strains and its inflammatory activity in the experimental model of meningitis. Med. Microbiol. Immunol. 190:135–138.
    OpenUrlPubMed
  23. 23.↵
    1. Bédos JP,
    2. Rolin O,
    3. Bouanchaud DH,
    4. Pocidalo JJ
    . 1991. Relationship between virulence and resistance to antibiotics in pneumococci. Contribution of experimental data obtained in an animal model. Pathol. Biol. 39:984–990.
    OpenUrlPubMed
  24. 24.↵
    1. Briles DE,
    2. Crain MJ,
    3. Gray BM,
    4. Forman C,
    5. Yother J
    . 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae . Infect. Immun. 60:111–116.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Russo TA,
    2. MacDonald U,
    3. Beanan JM,
    4. Olson R,
    5. MacDonald IJ,
    6. Sauberan SL,
    7. Luke NR,
    8. Schultz LW,
    9. Umland TC
    . 2009. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo . J. Infect. Dis. 199:513–521.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Cayo R,
    2. Rodriguez MC,
    3. Espinal P,
    4. Fernandez-Cuenca F,
    5. Ocampo-Sosa AA,
    6. Pascual A,
    7. Ayala JA,
    8. Vila J,
    9. Martinez-Martinez L
    . 2011. Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii . Antimicrob. Agents Chemother. 55:5907–5913.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Valat C,
    2. Haenni M,
    3. Saras E,
    4. Auvray F,
    5. Forest K,
    6. Oswald E,
    7. Madec JY
    . 2012. CTX-M-15 extended-spectrum beta-lactamase in a Shiga toxin-producing Escherichia coli isolate of serotype O111:H8. Appl. Environ. Microbiol. 78:1308–1309.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Ishii Y,
    2. Kimura S,
    3. Alba J,
    4. Shiroto K,
    5. Otsuka M,
    6. Hashizume N,
    7. Tamura K,
    8. Yamaguchi K
    . 2005. Extended-spectrum beta-lactamase-producing Shiga toxin gene (Stx1)-positive Escherichia coli O26:H11: a new concern. J. Clin. Microbiol. 43:1072–1075.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Cortes P,
    2. Blanc V,
    3. Mora A,
    4. Dahbi G,
    5. Blanco JE,
    6. Blanco M,
    7. Lopez C,
    8. Andreu A,
    9. Navarro F,
    10. Alonso MP,
    11. Bou G,
    12. Blanco J,
    13. Llangostera M
    . 2010. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl. Environ. Microbiol. 76:2799–2805.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Pitout JD,
    2. Laupland KB,
    3. Church DL,
    4. Menard ML,
    5. Johnson JR
    . 2005. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 49:4667–4670.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Peirano G,
    2. Schreckenberger PC,
    3. Pitout JD
    . 2011. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob. Agents Chemother. 55:2986–2988.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Dubois D,
    2. Prasadarao NV,
    3. Mittal R,
    4. Bret L,
    5. Roujou-Gris M,
    6. Bonnet R
    . 2009. CTX-M beta-lactamase production and virulence of Escherichia coli K1. Emerg. Infect. Dis. 15:1988–1990.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Aoki S,
    2. Hirakata Y,
    3. Kondoh A,
    4. Gotoh N,
    5. Yanagihara K,
    6. Miyazaki Y,
    7. Tomono K,
    8. Yamada Y,
    9. Kohno S,
    10. Kamihira S
    . 2004. Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo. Antimicrob. Agents Chemother. 48:1876–1878.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Fernandez A,
    2. Perez A,
    3. Ayala JA,
    4. Mallo S,
    5. Rumbo-Feal S,
    6. Tomas M,
    7. Poza M,
    8. Bou G
    . 2012. Expression of OXA-type and SFO-1 beta-lactamases induces changes in peptidoglycan composition and affects bacterial fitness. Antimicrob. Agents Chemother. 56:1877–1884.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Morosini MI,
    2. Ayala JA,
    3. Baquero F,
    4. Martinez JL,
    5. Blazquez J
    . 2000. Biological cost of AmpC production for Salmonella enterica serotype Typhimurium. Antimicrob. Agents Chemother. 44:3137–3143.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Sahly H,
    2. Navon-Venezia S,
    3. Roesler L,
    4. Hay A,
    5. Carmeli Y,
    6. Podschun R,
    7. Hennequin C,
    8. Forestier C,
    9. Ofek I
    . 2008. Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae . Antimicrob. Agents Chemother. 52:3029–3034.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Balasubramanian D,
    2. Schneper L,
    3. Merighi M,
    4. Smith R,
    5. Narasimhan G,
    6. Lory S,
    7. Mathee K
    . 2012. The regulatory repertoire of Pseudomonas aeruginosa AmpC β-lactamase regulator AmpR includes virulence genes PLoS One 7:e34067. doi:10.1371/journal.pone.0034067.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Kong KF,
    2. Jayawardena SR,
    3. Indulkar SD,
    4. Del Puerto A,
    5. Koh CL,
    6. Hoiby N,
    7. Mathee K
    . 2005. Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob. Agents Chemother. 49:4567–4575.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Hennequin C,
    2. Robin F,
    3. Cabrolier N,
    4. Bonnet R,
    5. Forestier C
    . 2012. Characterization of a DHA-1-producing Klebsiella pneumoniae strain involved in an outbreak and role of the AmpR regulator in virulence. Antimicrob. Agents Chemother. 56:288–294.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Dijkshoorn L,
    2. Nemec A,
    3. Seifert H
    . 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii . Nat. Rev. Microbiol. 5:939–951.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Sechi LA,
    2. Karadenizli A,
    3. Deriu A,
    4. Zanetti S,
    5. Kolayli F,
    6. Balikci E,
    7. Vahaboglu H
    . 2004. PER-1 type beta-lactamase production in Acinetobacter baumannii is related to cell adhesion. Med. Sci. Monit. 10:180–184.
    OpenUrl
  42. 42.↵
    1. Bou G,
    2. Oliver A,
    3. Martínez-Beltrán J
    . 2000. OXA-24: a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 44:1556–1561.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Santillana E,
    2. Beceiro A,
    3. Bou G,
    4. Romero A
    . 2007. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 104:5354–5359.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Acosta J,
    2. Merino M,
    3. Viedma E,
    4. Poza M,
    5. Sanz F,
    6. Otero JR,
    7. Chaves F,
    8. Bou G
    . 2011. Multidrug-resistant Acinetobacter baumannii harboring OXA-24 carbapenemase, Spain. Emerg. Infect. Dis. 17:1064–1067.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Rosado CJ,
    2. Kondos S,
    3. Bull TE,
    4. Kuiper MJ,
    5. Law RH,
    6. Buckle AM,
    7. Voskoboinik I,
    8. Bird PI,
    9. Trapani JA,
    10. Whisstock JC,
    11. Dunstone MA
    . 2008. The MACPF/CDC family of pore-forming toxins. Cell. Microbiol. 10:1765–1774.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Dorsey CW,
    2. Tolmasky ME,
    3. Crosa JH,
    4. Actis LA
    . 2003. Genetic organization of an Acinetobacter baumannii chromosomal region harbouring genes related to siderophore biosynthesis and transport. Microbiology 149:1227–1238.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Nikaido H
    . 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67:593–656.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Sugawara E,
    2. Nikaido H
    . 2012. OmpA is the principal nonspecific slow porin of Acinetobacter baumannii . J. Bacteriol. 194:4089–4096.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Lee JS,
    2. Choi CH,
    3. Kim JW,
    4. Lee JC
    . 2010. Acinetobacter baumannii outer membrane protein A induces dendritic cell death through mitochondrial targeting. J. Microbiol. 48:387–392.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Gaddy JA,
    2. Tomaras AP,
    3. Actis LA
    . 2009. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect. Immun. 77:3150–3160.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Cabral MP,
    2. Soares NC,
    3. Aranda J,
    4. Parreira JR,
    5. Rumbo C,
    6. Poza M,
    7. Valle J,
    8. Calamia V,
    9. Lasa I,
    10. Bou G
    . 2011. Proteomic and functional analyses reveal a unique lifestyle for Acinetobacter baumannii biofilms and a key role for histidine metabolism. J. Proteome Res. 10:3399–3417.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Limansky AS,
    2. Mussi MA,
    3. Viale AM
    . 2002. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol. 40:4776–4778.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. del Mar Tomás M,
    2. Beceiro A,
    3. Pérez A,
    4. Velasco D,
    5. Moure R,
    6. Villanueva R,
    7. Martínez-Beltrán J,
    8. Bou G
    . 2005. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii . Antimicrob. Agents Chemother. 49:5172–5175.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Catel-Ferreira M,
    2. Nehme R,
    3. Molle V,
    4. Aranda J,
    5. Bouffartigues E,
    6. Chevalier S,
    7. Bou G,
    8. Jouenne T,
    9. De E
    . 2012. Deciphering the function of the outer membrane protein OprD homologue of Acinetobacter baumannii . Antimicrob. Agents Chemother. 56:3826–3832.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Fernandez-Cuenca F,
    2. Smani Y,
    3. Gomez-Sanchez MC,
    4. Docobo-Perez F,
    5. Caballero-Moyano FJ,
    6. Dominguez-Herrera J,
    7. Pascual A,
    8. Pachon J
    . 2011. Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int. J. Antimicrob. Agents 38:548–549.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Smani Y,
    2. McConnell MJ,
    3. Pachón J
    . 2012. Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells. PLoS One 7:e33073. doi:10.1371/journal.pone.0033073.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Liu YF,
    2. Yan JJ,
    3. Lei HY,
    4. Teng CH,
    5. Wang MC,
    6. Tseng CC,
    7. Wu JJ
    . 2012. Loss of outer membrane protein C in Escherichia coli contributes to both antibiotic resistance and escaping antibody-dependent bactericidal activity. Infect. Immun. 80:1815–1822.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Rolhion N,
    2. Carvalho FA,
    3. Darfeuille-Michaud A
    . 2007. OmpC and the sigmaE regulatory pathway are involved in adhesion and invasion of the Crohn's disease-associated Escherichia coli strain LF82. Mol. Microbiol. 63:1684–1700.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Bekhit A,
    2. Fukamachi T,
    3. Saito H,
    4. Kobayashi H
    . 2011. The role of OmpC and OmpF in acidic resistance in Escherichia coli . Biol. Pharm. Bull. 34:330–334.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Chart H,
    2. Rowe B
    . 1989. The outer membrane protein of enteropathogenic Escherichia coli, described as the ‘localised adherence factor’, is OmpF and probably not involved in adhesion to HEp-2 cells. FEMS Microbiol. Lett. 52:291–295.
    OpenUrlPubMed
  61. 61.↵
    1. Duperthuy M,
    2. Binesse J,
    3. Le Roux F,
    4. Romestand B,
    5. Caro A,
    6. Got Givaudan A,
    7. Mazel D,
    8. Bachere E,
    9. Destoumieux-Garzon D
    . 2010. The major outer membrane protein OmpU of Vibrio splendidus contributes to host antimicrobial peptide resistance and is required for virulence in the oyster Crassostrea gigas. Environ. Microbiol. 12:951–963.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Fito-Boncompte L,
    2. Chapalain A,
    3. Bouffartigues E,
    4. Chaker H,
    5. Lesouhaitier O,
    6. Gicquel G,
    7. Bazire A,
    8. Madi A,
    9. Connil N,
    10. Veron W,
    11. Taupin L,
    12. Toussaint B,
    13. Cornelis P,
    14. Wei Q,
    15. Shioya K,
    16. Déziel E,
    17. Feuilloley MG,
    18. Orange N,
    19. Dufour A,
    20. Chevalier S
    . 2011. Full virulence of Pseudomonas aeruginosa requires OprF. Infect. Immun. 79:1176–1186.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Arhin A,
    2. Boucher C
    . 2010. The outer membrane protein OprQ and adherence of Pseudomonas aeruginosa to human fibronectin. Microbiology 156:1415–1423.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Tunbridge AJ,
    2. Stevanin TM,
    3. Lee M,
    4. Marriott HM,
    5. Moir JW,
    6. Read RC,
    7. Dockrell DH
    . 2006. Inhibition of macrophage apoptosis by Neisseria meningitidis requires nitric oxide detoxification mechanisms. Infect. Immun. 74:729–733.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Coudeyras S,
    2. Nakusi L,
    3. Charbonnel N,
    4. Forestier C
    . 2008. A tripartite efflux pump involved in gastrointestinal colonization by Klebsiella pneumoniae confers a tolerance response to inorganic acid. Infect. Immun. 76:4633–4641.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Evans K,
    2. Passador L,
    3. Srikumar R,
    4. Tsang E,
    5. Nezezon J,
    6. Poole K
    . 1998. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa . J. Bacteriol. 180:5443–5447.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Martinez JL,
    2. Sanchez MB,
    3. Martinez-Solano L,
    4. Hernandez A,
    5. Garmendia L,
    6. Fajardo A,
    7. Alvarez-Ortega C
    . 2009. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol. Rev. 33:430–449.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Piddock LJ
    . 2006. Multidrug-resistance efflux pumps—not just for resistance. Nat. Rev. Microbiol. 4:629–636.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Posadas DM,
    2. Martin FA,
    3. Sabio y Garcia JV,
    4. Spera JM,
    5. Delpino MV,
    6. Baldi P,
    7. Campos E,
    8. Cravero SL,
    9. Zorreguieta A
    . 2007. The TolC homologue of Brucella suis is involved in resistance to antimicrobial compounds and virulence. Infect. Immun. 75:379–389.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Lavigne JP,
    2. Sotto A,
    3. Nicolas-Chanoine MH,
    4. Bouziges N,
    5. Bourg G,
    6. Davin-Regli A,
    7. Pages JM
    . 2012. Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin. Microbiol. Infect. 18:539–545.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Gil H,
    2. Platz GJ,
    3. Forestal CA,
    4. Monfett M,
    5. Bakshi CS,
    6. Sellati TJ,
    7. Furie MB,
    8. Benach JL,
    9. Thanassi DG
    . 2006. Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc. Natl. Acad. Sci. U. S. A. 103:12897–12902.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Hirakata Y,
    2. Srikumar R,
    3. Poole K,
    4. Gotoh N,
    5. Suematsu T,
    6. Kohno S,
    7. Kamihira S,
    8. Hancock RE,
    9. Speert DP
    . 2002. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa . J. Exp. Med. 196:109–118.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Imuta N,
    2. Nishi J,
    3. Tokuda K,
    4. Fujiyama R,
    5. Manago K,
    6. Iwashita M,
    7. Sarantuya J,
    8. Kawano Y
    . 2008. The Escherichia coli efflux pump TolC promotes aggregation of enteroaggregative E. coli 042. Infect. Immun. 76:1247–1256.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Buckley AM,
    2. Webber MA,
    3. Cooles S,
    4. Randall LP,
    5. La Ragione RM,
    6. Woodward MJ,
    7. Piddock LJ
    . 2006. The AcrAB-TolC efflux system of Salmonella enterica serovar Typhimurium plays a role in pathogenesis. Cell. Microbiol. 8:847–856.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. Bina XR,
    2. Lavine CL,
    3. Miller MA,
    4. Bina JE
    . 2008. The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice. FEMS Microbiol. Lett. 279:226–233.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Bina XR,
    2. Provenzano D,
    3. Nguyen N,
    4. Bina JE
    . 2008. Vibrio cholerae RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. Infect. Immun. 76:3595–3605.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Bailey AM,
    2. Ivens A,
    3. Kingsley R,
    4. Cottell JL,
    5. Wain J,
    6. Piddock LJ
    . 2010. RamA, a member of the AraC/XylS family, influences both virulence and efflux in Salmonella enterica serovar Typhimurium. J. Bacteriol. 192:1607–1616.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Ferhat M,
    2. Atlan D,
    3. Vianney A,
    4. Lazzaroni JC,
    5. Doublet P,
    6. Gilbert C
    . 2009. The TolC protein of Legionella pneumophila plays a major role in multi-drug resistance and the early steps of host invasion. PLoS One 4:e7732. doi:10.1371/journal.pone.0007732.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Webber MA,
    2. Bailey AM,
    3. Blair JM,
    4. Morgan E,
    5. Stevens MP,
    6. Hinton JC,
    7. Ivens A,
    8. Wain J,
    9. Piddock LJ
    . 2009. The global consequence of disruption of the AcrAB-TolC efflux pump in Salmonella enterica includes reduced expression of SPI-1 and other attributes required to infect the host. J. Bacteriol. 191:4276–4285.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Chan YY,
    2. Chua KL
    . 2005. The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J. Bacteriol. 187:4707–4719.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Keeney D,
    2. Ruzin A,
    3. Bradford PA
    . 2007. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae . Microb. Drug Resist. 13:1–6.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    1. Keeney D,
    2. Ruzin A,
    3. McAleese F,
    4. Murphy E,
    5. Bradford PA
    . 2008. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli . J. Antimicrob. Chemother. 61:46–53.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Ruzin A,
    2. Keeney D,
    3. Bradford PA
    . 2005. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii . Antimicrob. Agents Chemother. 49:791–793.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Ruzin A,
    2. Visalli MA,
    3. Keeney D,
    4. Bradford PA
    . 2005. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae . Antimicrob. Agents Chemother. 49:1017–1022.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Visalli MA,
    2. Murphy E,
    3. Projan SJ,
    4. Bradford PA
    . 2003. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis . Antimicrob. Agents Chemother. 47:665–669.
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    1. Al-Karablieh N,
    2. Weingart H,
    3. Ullrich MS
    . 2009. The outer membrane protein TolC is required for phytoalexin resistance and virulence of the fire blight pathogen Erwinia amylovora . Microb. Biotechnol. 2:465–475.
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Brown DG,
    2. Swanson JK,
    3. Allen C
    . 2007. Two host-induced Ralstonia solanacearum genes, acrA and dinF, encode multidrug efflux pumps and contribute to bacterial wilt virulence. Appl. Environ. Microbiol. 73:2777–2786.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Lister IM,
    2. Raftery C,
    3. Mecsas J,
    4. Levy SB
    . 2012. Yersinia pestis AcrAB-TolC in antibiotic resistance and virulence. Antimicrob. Agents Chemother. 56:1120–1123.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Perez A,
    2. Poza M,
    3. Fernandez A,
    4. Mdel Fernandez CC,
    5. Mallo S,
    6. Merino M,
    7. Rumbo-Feal S,
    8. Cabral MP,
    9. Bou G
    . 2012. Involvement of the AcrAB-TolC efflux pump in the resistance, fitness, and virulence of Enterobacter cloacae . Antimicrob. Agents Chemother. 56:2084–2090.
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Padilla E,
    2. Llobet E,
    3. Domenech-Sanchez A,
    4. Martinez-Martinez L,
    5. Bengoechea JA,
    6. Alberti S
    . 2010. Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. Antimicrob. Agents Chemother. 54:177–183.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    1. Bialek S,
    2. Lavigne JP,
    3. Chevalier J,
    4. Marcon E,
    5. Leflon-Guibout V,
    6. Davin A,
    7. Moreau R,
    8. Pages JM,
    9. Nicolas-Chanoine MH
    . 2010. Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob. Agents Chemother. 54:4373–4378.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Poole K,
    2. Gotoh N,
    3. Tsujimoto H,
    4. Zhao Q,
    5. Wada A,
    6. Yamasaki T,
    7. Neshat S,
    8. Yamagishi J,
    9. Li XZ,
    10. Nishino T
    . 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa . Mol. Microbiol. 21:713–724.
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.↵
    1. Köhler T,
    2. Michéa-Hamzehpour M,
    3. Henze U,
    4. Gotoh N,
    5. Curty LK,
    6. Pechère JC
    . 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa . Mol. Microbiol. 23:345–354.
    OpenUrlCrossRefPubMedWeb of Science
  94. 94.↵
    1. Sanchez P,
    2. Linares JF,
    3. Ruiz-Diez B,
    4. Campanario E,
    5. Navas A,
    6. Baquero F,
    7. Martinez JL
    . 2002. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother. 50:657–664.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    1. Linares JF,
    2. Lopez JA,
    3. Camafeita E,
    4. Albar JP,
    5. Rojo F,
    6. Martinez JLJ
    . 2005. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa . J. Bacteriol. 187:1384–1391.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Köhler T,
    2. van Delden C,
    3. Curty LK,
    4. Hamzehpour MM,
    5. Pechere JC
    . 2001. Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa . J. Bacteriol. 183:5213–5222.
    OpenUrlAbstract/FREE Full Text
  97. 97.↵
    1. Salunkhe P,
    2. Smart CH,
    3. Morgan JA,
    4. Panagea S,
    5. Walshaw MJ,
    6. Hart CA,
    7. Geffers R,
    8. Tummler B,
    9. Winstanley C
    . 2005. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J. Bacteriol. 187:4908–4920.
    OpenUrlAbstract/FREE Full Text
  98. 98.↵
    1. Tomas M,
    2. Doumith M,
    3. Warner M,
    4. Turton JF,
    5. Beceiro A,
    6. Bou G,
    7. Livermore DM,
    8. Woodford N
    . 2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 54:2219–2224.
    OpenUrlAbstract/FREE Full Text
  99. 99.↵
    1. Maeda T,
    2. García-Contreras R,
    3. Pu M,
    4. Sheng L,
    5. Garcia LR,
    6. Tomás M,
    7. Wood TK
    . 2012. Quorum quenching quandary: resistance to antivirulence compounds. ISME J. 6:493–501.
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Burrowes E,
    2. Baysse C,
    3. Adams C,
    4. O'Gara F
    . 2006. Influence of the regulatory protein RsmA on cellular functions in Pseudomonas aeruginosa PAO1: as revealed by transcriptome analysis. Microbiology 152:405–418.
    OpenUrlCrossRefPubMedWeb of Science
  101. 101.↵
    1. Lamarche MG,
    2. Deziel E
    . 2011. MexEF-OprN efflux pump exports the Pseudomonas quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline). PLoS One 6:e24310. doi:10.1371/journal.pone.0024310.
    OpenUrlCrossRefPubMed
  102. 102.↵
    1. Minagawa S,
    2. Inami H,
    3. Kato T,
    4. Sawada S,
    5. Yasuki T,
    6. Miyairi S,
    7. Horikawa M,
    8. Okuda J,
    9. Gotoh N
    . 2012. RND type efflux pump system MexAB-OprM of Pseudomonas aeruginosa selects bacterial languages, 3-oxo-acyl-homoserine lactones, for cell-to-cell communication. BMC Microbiol. 12:70.
    OpenUrlCrossRefPubMed
  103. 103.↵
    1. Quiblier C,
    2. Zinkernagel AS,
    3. Schuepbach RA,
    4. Berger-Bachi B,
    5. Senn MM
    . 2011. Contribution of SecDF to Staphylococcus aureus resistance and expression of virulence factors. BMC Microbiol. 11:72.
    OpenUrlCrossRefPubMed
  104. 104.↵
    1. Gutierrez B,
    2. Escudero JA,
    3. San Millan A,
    4. Hidalgo L,
    5. Carrilero L,
    6. Ovejero CM,
    7. Santos-Lopez A,
    8. Thomas-Lopez D,
    9. Gonzalez-Zorn B
    . 2012. Fitness cost and interference of Arm/Rmt aminoglycoside resistance with the RsmF housekeeping methyltransferases. Antimicrob. Agents Chemother. 56:2335–2341.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    1. Poole K
    . 2005. Aminoglycoside resistance in Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 49:479–487.
    OpenUrlFREE Full Text
  106. 106.↵
    1. Fournier PE,
    2. Vallenet D,
    3. Barbe V,
    4. Audic S,
    5. Ogata H,
    6. Poirel L,
    7. Richet H,
    8. Robert C,
    9. Mangenot S,
    10. Abergel C,
    11. Nordmann P,
    12. Weissenbach J,
    13. Raoult D,
    14. Claverie JM
    . 2006. Comparative genomics of multidrug resistance in Acinetobacter baumannii . PLoS Genet. 2:e7. doi:10.1371/journal.pgen.0020007.
    OpenUrlCrossRefPubMed
  107. 107.↵
    1. Juan C,
    2. Mulet X,
    3. Zamorano L,
    4. Albertí S,
    5. Pérez JL,
    6. Oliver A
    . 2009. Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrob. Agents Chemother. 53:5288–5290.
    OpenUrlAbstract/FREE Full Text
  108. 108.↵
    1. Pérez-Llarena FJ,
    2. Fernández A,
    3. Zamorano L,
    4. Kerff F,
    5. Beceiro A,
    6. Aracil B,
    7. Cercenado E,
    8. Miro E,
    9. Oliver A,
    10. Oteo J,
    11. Navarro F,
    12. Bou G
    . 2012. Characterizacion of a novel IMP-28 metallo-β-lactamase from a spanish Klebsiella oxytoca clinical isolate. Antimicrob. Agents Chemother. 56:4540–4543.
    OpenUrlAbstract/FREE Full Text
  109. 109.↵
    1. Perez A,
    2. Canle D,
    3. Latasa C,
    4. Poza M,
    5. Beceiro A,
    6. Tomas Mdel M,
    7. Fernandez A,
    8. Mallo S,
    9. Perez S,
    10. Molina F,
    11. Villanueva R,
    12. Lasa I,
    13. Bou G
    . 2007. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob. Agents Chemother. 51:3247–3253.
    OpenUrlAbstract/FREE Full Text
  110. 110.↵
    1. Coyne S,
    2. Courvalin P,
    3. Perichon B
    . 2011. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob. Agents Chemother. 55:947–953.
    OpenUrlAbstract/FREE Full Text
  111. 111.↵
    1. Olkkola S,
    2. Juntunen P,
    3. Heiska H,
    4. Hyytiainen H,
    5. Hanninen ML
    . 2010. Mutations in the rpsL gene are involved in streptomycin resistance in Campylobacter coli . Microb. Drug Resist. 16:105–110.
    OpenUrlCrossRefPubMed
  112. 112.↵
    1. Paulander W,
    2. Maisnier-Patin S,
    3. Andersson DI
    . 2009. The fitness cost of streptomycin resistance depends on rpsL mutation, carbon source and RpoS (sigmaS). Genetics 183:539–546.
    OpenUrlAbstract/FREE Full Text
  113. 113.↵
    1. Christensen EG,
    2. Gram L,
    3. Kastbjerg VG
    . 2011. Sublethal triclosan exposure decreases susceptibility to gentamicin and other aminoglycosides in Listeria monocytogenes . Antimicrob. Agents Chemother. 55:4064–4071.
    OpenUrlAbstract/FREE Full Text
  114. 114.↵
    1. Sun YJ,
    2. Luo JT,
    3. Wong SY,
    4. Lee AS
    . 2010. Analysis of rpsL and rrs mutations in Beijing and non-Beijing streptomycin-resistant Mycobacterium tuberculosis isolates from Singapore. Clin. Microbiol. Infect. 16:287–289.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.↵
    1. Zarazaga M,
    2. Tenorio C,
    3. Del Campo R,
    4. Ruiz-Larrea F,
    5. Torres C
    . 2002. Mutations in ribosomal protein L16 and in 23S rRNA in Enterococcus strains for which evernimicin MICs differ. Antimicrob. Agents Chemother. 46:3657–3659.
    OpenUrlAbstract/FREE Full Text
  116. 116.↵
    1. Aslangul E,
    2. Massias L,
    3. Meulemans A,
    4. Chau F,
    5. Andremont A,
    6. Courvalin P,
    7. Fantin B,
    8. Ruimy R
    . 2006. Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis . Antimicrob. Agents Chemother. 50:3615–3621.
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Rice LB
    . 2012. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin. Proc. 87:198–208.
    OpenUrlCrossRefPubMedWeb of Science
  118. 118.↵
    1. Pomba C,
    2. da Fonseca JD,
    3. Baptista BC,
    4. Correia JD,
    5. Martínez-Martínez L
    . 2009. Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac6′-Ib-cr genes in a dog. Antimicrob. Agents Chemother. 53:327–328.
    OpenUrlFREE Full Text
  119. 119.↵
    1. Kugelberg E,
    2. Lofmark S,
    3. Wretlind B,
    4. Andersson DI
    . 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa . J. Antimicrob. Chemother. 55:22–30.
    OpenUrlCrossRefPubMedWeb of Science
  120. 120.↵
    1. O'Regan E,
    2. Quinn T,
    3. Frye JG,
    4. Pages JM,
    5. Porwollik S,
    6. Fedorka-Cray PJ,
    7. McClelland M,
    8. Fanning S
    . 2010. Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype Enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes. Antimicrob. Agents Chemother. 54:367–374.
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    1. Smani Y,
    2. Lopez-Rojas R,
    3. Dominguez-Herrera J,
    4. Docobo-Perez F,
    5. Marti S,
    6. Vila J,
    7. Pachon J
    . 2012. In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii . Clin. Microbiol. Infect. 18:E1–E4.
    OpenUrlCrossRefPubMed
  122. 122.↵
    1. Rossolini GM,
    2. Mantengoli E,
    3. Montagnani F,
    4. Pollini S
    . 2010. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. Opin. Microbiol. 13:582–588.
    OpenUrlCrossRefPubMed
  123. 123.↵
    1. Helms M,
    2. Simonsen J,
    3. Molbak K
    . 2004. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. J. Infect. Dis. 190:1652–1654.
    OpenUrlCrossRefPubMedWeb of Science
  124. 124.↵
    1. McNairn E,
    2. Ni Bhriain N,
    3. Dorman CJ
    . 1995. Overexpression of the Shigella flexneri genes coding for DNA topoisomerase IV compensates for loss of DNA topoisomerase I: effect on virulence gene expression. Mol. Microbiol. 15:507–517.
    OpenUrlCrossRefPubMed
  125. 125.↵
    1. Kishii R,
    2. Takei M
    . 2009. Relationship between the expression of ompF and quinolone resistance in Escherichia coli . J. Infect. Chemother. 15:361–366.
    OpenUrlCrossRefPubMed
  126. 126.↵
    1. Tran QT,
    2. Nawaz MS,
    3. Deck J,
    4. Foley S,
    5. Nguyen K,
    6. Cerniglia CE
    . 2011. Detection of type III secretion system virulence and mutations in gyrA and parC genes among quinolone-resistant strains of Pseudomonas aeruginosa isolated from imported shrimp. Foodborne Pathog. Dis. 8:451–453.
    OpenUrlCrossRefPubMed
  127. 127.↵
    1. Wong-Beringer A,
    2. Wiener-Kronish J,
    3. Lynch S,
    4. Flanagan J
    . 2008. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa . Clin. Microbiol. Infect. 14:330–336.
    OpenUrlCrossRefPubMed
  128. 128.↵
    1. Agnello M,
    2. Wong-Beringer A
    . 2012. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa . PLoS One 7:e42973. doi:10.1371/journal.pone.0042973.
    OpenUrlCrossRefPubMed
  129. 129.↵
    1. Lamichhane-Khadka R,
    2. Cantore SA,
    3. Riordan JT,
    4. Delgado A,
    5. Norman AE,
    6. Duenas S,
    7. Zaman S,
    8. Horan S,
    9. Wilkinson BJ,
    10. Gustafson JE
    . 2009. sarA inactivation reduces vancomycin-intermediate and ciprofloxacin resistance expression by Staphylococcus aureus . Int. J. Antimicrob. Agents 34:136–141.
    OpenUrlCrossRefPubMed
  130. 130.↵
    1. Cirz RT,
    2. Jones MB,
    3. Gingles NA,
    4. Minogue TD,
    5. Jarrahi B,
    6. Peterson SN,
    7. Romesberg FE
    . 2007. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J. Bacteriol. 189:531–539.
    OpenUrlAbstract/FREE Full Text
  131. 131.↵
    1. Bisognano C,
    2. Kelley WL,
    3. Estoppey T,
    4. Francois P,
    5. Schrenzel J,
    6. Li D,
    7. Lew DP,
    8. Hooper DC,
    9. Cheung AL,
    10. Vaudaux P
    . 2004. A recA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus . J. Biol. Chem. 279:9064–9071.
    OpenUrlAbstract/FREE Full Text
  132. 132.↵
    1. Johnson CN,
    2. Briles DE,
    3. Benjamin WH Jr,
    4. Hollingshead SK,
    5. Waites KB
    . 2005. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae . Emerg. Infect. Dis. 11:814–820.
    OpenUrlPubMedWeb of Science
  133. 133.↵
    1. Truong-Bolduc QC,
    2. Hooper DC
    . 2010. Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus . J. Bacteriol. 192:2525–2534.
    OpenUrlAbstract/FREE Full Text
  134. 134.↵
    1. Martin FA,
    2. Posadas DM,
    3. Carrica MC,
    4. Cravero SL,
    5. O'Callaghan D,
    6. Zorreguieta A
    . 2009. Interplay between two RND systems mediating antimicrobial resistance in Brucella suis . J. Bacteriol. 191: 2530–2540.
    OpenUrlAbstract/FREE Full Text
  135. 135.↵
    1. Alonso A,
    2. Martínez JL
    . 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia . Antimicrob. Agents Chemother. 44:3079–3086.
    OpenUrlAbstract/FREE Full Text
  136. 136.↵
    1. Alonso A,
    2. Morales G,
    3. Escalante R,
    4. Campanario E,
    5. Sastre L,
    6. Martinez JL
    . 2004. Overexpression of the multidrug efflux pump SmeDEF impairs Stenotrophomonas maltophilia physiology. J. Antimicrob. Chemother. 53: 432–434.
    OpenUrlCrossRefPubMedWeb of Science
  137. 137.↵
    1. Cattoir V,
    2. Nordmann P
    . 2009. Plasmid-mediated quinolone resistance in gram-negative bacterial species: an update. Curr. Med. Chem. 16:1028–1046.
    OpenUrlCrossRefPubMedWeb of Science
  138. 138.↵
    1. Michon A,
    2. Allou N,
    3. Chau F,
    4. Podglajen I,
    5. Fantin B,
    6. Cambau E
    . 2011. Plasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure. PLoS One 6:e24552. doi:10.1371/journal.pone.0024552.
    OpenUrlCrossRefPubMed
  139. 139.↵
    1. Speer BS,
    2. Shoemaker NB,
    3. Salyers AA
    . 1992. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin. Microbiol. Rev. 5:387–399.
    OpenUrlAbstract/FREE Full Text
  140. 140.↵
    1. Karami N,
    2. Nowrouzian F,
    3. Adlerberth I,
    4. Wold AE
    . 2006. Tetracycline resistance in Escherichia coli and persistence in the infantile colonic microbiota. Antimicrob. Agents Chemother. 50:156–161.
    OpenUrlAbstract/FREE Full Text
  141. 141.↵
    1. Beutlich J,
    2. Jahn S,
    3. Malorny B,
    4. Hauser E,
    5. Hühn S,
    6. Schroeter A,
    7. Rodicio MR,
    8. Appel B,
    9. Threlfall J,
    10. Mevius D,
    11. Guerra B
    . 2011. Antimicrobial resistance and virulence determinants in European Salmonella genomic island 1-positive Salmonella enterica isolates from different origins. Appl. Environ. Microbiol. 77:5655–5664.
    OpenUrlAbstract/FREE Full Text
  142. 142.↵
    1. Abril C,
    2. Brodard I,
    3. Perreten V
    . 2010. Two novel antibiotic resistance genes, tet44 and ant6-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus . Antimicrob. Agents Chemother. 54:3052–3055.
    Op